##analysisDate=2017-09-08-17-17-47000
##analyzedBy=RingStudy Site F
##exportDate=2017-11-08-11-19-44000
##analysisName=Site F-092-Sample 6-SE17-0230-Ring_Study-OCAv3_REPEAT
##workflowName=Oncomine Comprehensive v3 - w2.1 - DNA and Fusions - Single Sample
##sampleNames=SE17-0230_v1:SE17-0230_RNA_v1
##reference=hg19
##variantGroup=DEFAULT
##filterChain=Site D_NoRef
##searchText=
##chromosome=All
##totalVariantCount=2506
##filterInCount=122
##filteredOutCount=2384
##hiddenVariantCount=0
Locus	Genotype	Ref	Type	No Call Reason	Genes	Location	Length	Oncomine Variant Class	Oncomine Gene Class	Copy Number	CytoBand	Info	Variant ID	Variant Name	% Frequency	Amino Acid Change	Read Counts	Coverage	Allele Ratio	CNV Confidence	Detection	3'/5' Imbalance	COSMIC/NCBI	Read Counts Per Million	Strand	Exon	Transcript	Coding	Variant Effect	PhyloP	SIFT	Grantham	PolyPhen	PFAM	dbSNP	DGV	MAF	EMAF	AMAF	GMAF	UCSC Common SNPs	Gene Ontology	DrugBank	ClinVar	p-value	Phred QUAL Score	Allele Coverage	CNV Precision	Ref+/Ref-/Var+/Var-	Homopolymer Length	Tiles
chr1:11168332	A/T	A	SNV		MTOR	exonic	1								6.02	p.Ser2514Thr		299	A=0.9398, T=0.0602		Present				-	57	NM_004958.3	c.7540T>A	missense	2.17	0.04	58.0	0.095	FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase	rs370135897			1.0E-4	0.0	1.0E-4		ATP binding,Golgi apparatus,Golgi membrane,PML body,RNA polymerase III type 1 promoter DNA binding,RNA polymerase III type 2 promoter DNA binding,RNA polymerase III type 3 promoter DNA binding,T cell costimulation,TFIIIC-class transcription factor binding,TOR signaling cascade,TORC1 complex,TORC2 complex,cell growth,cellular response to hypoxia,cellular response to nutrient levels,cytoplasm,cytosol,dendrite,endomembrane system,endoplasmic reticulum,endoplasmic reticulum membrane,fibroblast growth factor receptor signaling pathway,germ cell development,growth,insulin receptor signaling pathway,kinase activity,lysosome,mTOR-FKBP12-rapamycin complex,membrane,mitochondrial outer membrane,mitochondrion,negative regulation of NFAT protein import into nucleus,negative regulation of autophagy,negative regulation of cell size,negative regulation of macroautophagy,nerve growth factor receptor signaling pathway,neuronal cell body,nucleotide binding,nucleus,peptidyl-serine phosphorylation,peptidyl-threonine phosphorylation,phosphatidylinositol 3-kinase complex,phosphatidylinositol-mediated signaling,phosphoprotein binding,phosphorylation,phosphotransferase activity, alcohol group as acceptor,positive regulation of actin filament polymerization,positive regulation of endothelial cell proliferation,positive regulation of lamellipodium assembly,positive regulation of lipid biosynthetic process,positive regulation of peptidyl-tyrosine phosphorylation,positive regulation of protein kinase B signaling cascade,positive regulation of protein phosphorylation,positive regulation of stress fiber assembly,positive regulation of transcription from RNA polymerase III promoter,positive regulation of translation,protein autophosphorylation,protein binding,protein catabolic process,protein domain specific binding,protein phosphorylation,protein serine/threonine kinase activity,regulation of Rac GTPase activity,regulation of actin cytoskeleton organization,regulation of carbohydrate metabolic process,regulation of carbohydrate utilization,regulation of fatty acid beta-oxidation,regulation of glycogen biosynthetic process,regulation of protein kinase activity,regulation of response to food,response to amino acid stimulus,response to insulin stimulus,response to nutrient,ribosome binding,ruffle organization,signal transduction,soluble fraction	Everolimus,Pimecrolimus,Sirolimus,Temsirolimus		0.00206	26.8645	A=281, T=18		A=145/136, T=10/8	1	
chr1:27057673	G/A	G	SNV		ARID1A	exonic	1								27.24	p.Gly461Arg		1916	G=0.7276, A=0.2724		Present				+	3	NM_006015.4	c.1381G>A	missense	2.62	0.0	125.0	0.999	ARID/BRIGHT DNA binding domain								DNA binding,SWI/SNF complex,androgen receptor signaling pathway,chromatin remodeling,chromatin-mediated maintenance of transcription,glucocorticoid receptor signaling pathway,intracellular,intracellular estrogen receptor signaling pathway,ligand-dependent nuclear receptor binding,nBAF complex,nervous system development,npBAF complex,nuclear chromatin,nucleolus,nucleosome disassembly,nucleosome mobilization,nucleus,positive regulation of transcription, DNA-dependent,protein binding,regulation of transcription from RNA polymerase II promoter,transcription coactivator activity			0.00001	3300.93	G=1394, A=522		G=727/667, A=280/242	3	
chr1:40363054	G/C	G	SNV		MYCL	exonic	1								48.80	p.Thr392Ser		125	G=0.512, C=0.488		Present				-	3	NM_001033082.2	c.1175C>G	missense	1.32	1.0	58.0	0.0	Helix-loop-helix DNA-binding domain,Myc amino-terminal region	rs3134614		0.055 (ref)	0.1328	0.0252	0.0963	YES	DNA binding,nucleus,regulation of transcription, DNA-dependent,sequence-specific DNA binding transcription factor activity			0.00001	542.668	G=64, C=61		G=33/31, C=25/36	1	
chr1:65310489	T/C	T	SNV		JAK1	exonic	1								53.78	p.(=)		331	T=0.4622, C=0.5378		Present				-	16	NM_002227.2	c.2199A>G	synonymous	-4.13				Protein kinase domain,Protein tyrosine kinase	rs2230588		0.352 (ref)	0.2323	0.418	0.3492	YES	ATP binding,cytokine-mediated signaling pathway,cytoplasm,cytoskeleton,cytosol,endomembrane system,growth hormone receptor binding,interferon-gamma-mediated signaling pathway,intracellular protein kinase cascade,intracellular signal transduction,membrane,non-membrane spanning protein tyrosine kinase activity,nucleotide binding,nucleus,protein binding,protein phosphorylation,protein tyrosine kinase activity,regulation of interferon-gamma-mediated signaling pathway,regulation of type I interferon-mediated signaling pathway,response to antibiotic,type I interferon-mediated signaling pathway	2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZH-IMIDAZ4,5-FISOQUINOLIN-7-ONE,3-{(3R,4R)-4-methyl-3-methyl(7H-pyrrolo2,3-dpyrimidin-4-yl)aminopiperidin-1-yl}-3-oxopropanenitrile		0.00001	1718.62	T=153, C=178		T=87/66, C=102/76	1	
chr1:204494724		G	GENE_EXPRESSION		MDM4								MDM4.E3E4				43				NoCall			1.3408e-08																						0.0					
chr2:47693929	G/A	G	SNV		MSH2	exonic	1								6.36	p.Gly548Asp		110	G=0.9364, A=0.0636		Present				+	10	NM_000251.2	c.1643G>A	missense	2.87	0.0	94.0	1.0	MutS domain I,MutS domain II,MutS domain III,MutS domain V,MutS family domain IV								ADP binding,ATP binding,ATP catabolic process,ATPase activity,B cell differentiation,B cell mediated immunity,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis,DNA repair,DNA-dependent ATPase activity,MutLalpha complex binding,MutSalpha complex,MutSbeta complex,Y-form DNA binding,cell cycle arrest,centromeric DNA binding,damaged DNA binding,determination of adult lifespan,dinucleotide insertion or deletion binding,dinucleotide repeat insertion binding,double-strand break repair,double-strand/single-strand DNA junction binding,double-stranded DNA binding,enzyme binding,four-way junction DNA binding,germ cell development,guanine/thymine mispair binding,in utero embryonic development,intra-S DNA damage checkpoint,isotype switching,loop DNA binding,magnesium ion binding,maintenance of DNA repeat elements,male gonad development,meiotic gene conversion,meiotic mismatch repair,mismatch repair,mismatched DNA binding,negative regulation of DNA recombination,negative regulation of neuron apoptosis,negative regulation of reciprocal meiotic recombination,nuclear chromosome,nucleotide binding,nucleus,oxidative phosphorylation,oxidized purine DNA binding,positive regulation of helicase activity,postreplication repair,protein C-terminus binding,protein binding,protein homodimerization activity,protein kinase binding,response to UV-B,response to X-ray,response to amino acid stimulus,response to drug,response to organic cyclic compound,single guanine insertion binding,single thymine insertion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments,spermatogenesis			0.02103	16.7721	G=103, A=7		G=37/66, A=1/6	2	
chr2:47710032	G/A	G	SNV		MSH2	exonic	1								5.56	p.Ala917Thr		90	G=0.9444, A=0.0556		Present				+	16	NM_000251.2	c.2749G>A	missense	2.54	0.02	58.0	0.027	MutS domain I,MutS domain II,MutS domain III,MutS domain V,MutS family domain IV	rs200581817		0.0 (ref)					ADP binding,ATP binding,ATP catabolic process,ATPase activity,B cell differentiation,B cell mediated immunity,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis,DNA repair,DNA-dependent ATPase activity,MutLalpha complex binding,MutSalpha complex,MutSbeta complex,Y-form DNA binding,cell cycle arrest,centromeric DNA binding,damaged DNA binding,determination of adult lifespan,dinucleotide insertion or deletion binding,dinucleotide repeat insertion binding,double-strand break repair,double-strand/single-strand DNA junction binding,double-stranded DNA binding,enzyme binding,four-way junction DNA binding,germ cell development,guanine/thymine mispair binding,in utero embryonic development,intra-S DNA damage checkpoint,isotype switching,loop DNA binding,magnesium ion binding,maintenance of DNA repeat elements,male gonad development,meiotic gene conversion,meiotic mismatch repair,mismatch repair,mismatched DNA binding,negative regulation of DNA recombination,negative regulation of neuron apoptosis,negative regulation of reciprocal meiotic recombination,nuclear chromosome,nucleotide binding,nucleus,oxidative phosphorylation,oxidized purine DNA binding,positive regulation of helicase activity,postreplication repair,protein C-terminus binding,protein binding,protein homodimerization activity,protein kinase binding,response to UV-B,response to X-ray,response to amino acid stimulus,response to drug,response to organic cyclic compound,single guanine insertion binding,single thymine insertion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments,spermatogenesis			0.05992	12.2241	G=85, A=5		G=43/42, A=3/2	1	
chr2:209113192	G/A	G	SNV		IDH1	exonic	1								50.53	p.(=)		281	G=0.4947, A=0.5053		Present				-	4	NM_005896.3	c.315C>T	synonymous	1.35				Isocitrate/isopropylmalate dehydrogenase	rs11554137		0.049 (ref)	0.0531	0.106	0.071	YES	2-oxoglutarate metabolic process,NAD binding,NADPH regeneration,carbohydrate metabolic process,cellular lipid metabolic process,cytoplasm,cytosol,glutathione metabolic process,glyoxylate cycle,isocitrate dehydrogenase (NADP+) activity,isocitrate metabolic process,magnesium ion binding,mitochondrion,oxidoreductase activity,oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,peroxisomal matrix,peroxisome,protein homodimerization activity,response to oxidative stress,tricarboxylic acid cycle	2'-Monophosphoadenosine 5'-Diphosphoribose,Isocitric Acid		0.00001	1323.53	G=139, A=142		G=72/67, A=68/74	1	
chr3:10116316	C/T	C	SNV		FANCD2	exonic	1								6.76	p.Leu940Phe		74	C=0.9324, T=0.0676		Present				+	29	NM_033084.3	c.2818C>T	missense	0.82	0.03	22.0	1.0									DNA repair,cell cycle,condensed chromosome,gamete generation,nucleoplasm,nucleus,protein binding,response to gamma radiation,synapsis			0.02961	15.2851	C=69, T=5		C=29/40, T=1/4	1	
chr3:10128928	C/T	C	SNV		FANCD2,FANCD2OS	exonic, intronic	1								3.76	p.Ala1149Val		904	C=0.9624, T=0.0376		Present				+, -	34	NM_033084.3, NM_173472.1	c.3446C>T	missense	1.32	0.67	64.0	0.199		rs147675860		0.004 (ref)	0.0	0.0018	6.0E-4		DNA repair,cell cycle,condensed chromosome,gamete generation,nucleoplasm,nucleus,protein binding,response to gamma radiation,synapsis			0.07333	11.3472	C=870, T=34		C=491/379, T=15/19	1	
chr3:37053568	A/G	A	SNV		MLH1	exonic	1								50.20	p.Ile219Val		1536	A=0.498, G=0.502		Present				+	8	NM_000249.3	c.655A>G	missense	2.21	0.17	29.0	0.018	DNA mismatch repair protein,Histidine kinase-	rs1799977		0.172	0.3202	0.0921	0.243	YES	ATP binding,ATP catabolic process,ATPase activity,DNA damage response, signal transduction resulting in induction of apoptosis,MutLalpha complex,MutLbeta complex,MutSalpha complex binding,cell cycle,cellular response to organic cyclic compound,chiasma,double-strand break repair via nonhomologous end joining,guanine/thymine mispair binding,isotype switching,male germ cell nucleus,male meiosis chromosome segregation,meiotic metaphase I plate congression,mismatch repair,mismatched DNA binding,negative regulation of mitotic recombination,nuclear-transcribed mRNA poly(A) tail shortening,nucleus,oogenesis,pachytene,protein binding,reciprocal meiotic recombination,resolution of meiotic recombination intermediates,response to drug,response to hypoxia,response to toxin,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,spermatogenesis,spindle midzone assembly involved in meiosis,synaptonemal complex		non-pathogenic,probable-non-pathogenic	0.00001	7235.77	A=765, G=771		A=329/436, G=402/369	1	
chr3:142184045	ATCT/A	ATCT	INDEL		ATR	exonic	3								31.74	p.Lys2311del		1796	ATCT=0.6826, A=0.3174		Present				-	41	NM_001184.3	c.6932_6934delAGA	nonframeshiftDeletion	1.96,1.96,-0.34,1.96				FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase,UME (NUC010) domain								ATP binding,DNA binding,DNA damage checkpoint,DNA repair,DNA replication,MutLalpha complex binding,MutSalpha complex binding,PML body,XY body,cell cycle,cell cycle checkpoint,cellular response to UV,cellular response to gamma radiation,multicellular organismal development,negative regulation of DNA replication,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,protein autophosphorylation,protein binding,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of protein binding,replicative senescence,response to DNA damage stimulus			0.00001	3960.13	ATCT=1226, A=570		ATCT=610/616, A=305/265	1	
chr3:142222284	A/G	A	SNV		ATR	exonic	1								46.71	p.(=)		334	A=0.5329, G=0.4671		Present				-	30	NM_001184.3	c.5208T>C	synonymous	0.03				FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase,UME (NUC010) domain	rs2227931		0.352 (ref)	0.4189	0.2145	0.3496	YES	ATP binding,DNA binding,DNA damage checkpoint,DNA repair,DNA replication,MutLalpha complex binding,MutSalpha complex binding,PML body,XY body,cell cycle,cell cycle checkpoint,cellular response to UV,cellular response to gamma radiation,multicellular organismal development,negative regulation of DNA replication,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,protein autophosphorylation,protein binding,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of protein binding,replicative senescence,response to DNA damage stimulus			0.00001	1383.7	A=178, G=156		A=77/101, G=83/73	1	
chr3:142277536	A/G	A	SNV		ATR	exonic	1								47.99	p.(=)		871	A=0.5201, G=0.4799		Present				-	8	NM_001184.3	c.1815T>C	synonymous	0.12				FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase,UME (NUC010) domain	rs2227929		0.349 (ref)	0.414	0.2127	0.3458	YES	ATP binding,DNA binding,DNA damage checkpoint,DNA repair,DNA replication,MutLalpha complex binding,MutSalpha complex binding,PML body,XY body,cell cycle,cell cycle checkpoint,cellular response to UV,cellular response to gamma radiation,multicellular organismal development,negative regulation of DNA replication,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,protein autophosphorylation,protein binding,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of protein binding,replicative senescence,response to DNA damage stimulus			0.00001	3828.57	A=453, G=418		A=246/207, G=207/211	1	
chr3:142277575	A/T	A	SNV		ATR	exonic	1								46.59	p.(=)		264	A=0.5341, T=0.4659		Present				-	8	NM_001184.3	c.1776T>A	synonymous	-0.09				FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase,UME (NUC010) domain	rs2227930		0.382 (ref)	0.405	0.2043	0.337	YES	ATP binding,DNA binding,DNA damage checkpoint,DNA repair,DNA replication,MutLalpha complex binding,MutSalpha complex binding,PML body,XY body,cell cycle,cell cycle checkpoint,cellular response to UV,cellular response to gamma radiation,multicellular organismal development,negative regulation of DNA replication,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,protein autophosphorylation,protein binding,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of protein binding,replicative senescence,response to DNA damage stimulus			0.00001	1101.15	A=141, T=123		A=78/63, T=54/69	1	
chr3:142281612	A/G	A	SNV		ATR	exonic	1								55.15	p.Met211Thr		301	A=0.4485, G=0.5515		Present				-	4	NM_001184.3	c.632T>C	missense	0.55	1.0	81.0	0.0	FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase,UME (NUC010) domain	rs2227928		0.383 (ref)	0.4045	0.2072	0.3377	YES	ATP binding,DNA binding,DNA damage checkpoint,DNA repair,DNA replication,MutLalpha complex binding,MutSalpha complex binding,PML body,XY body,cell cycle,cell cycle checkpoint,cellular response to UV,cellular response to gamma radiation,multicellular organismal development,negative regulation of DNA replication,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,protein autophosphorylation,protein binding,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of protein binding,replicative senescence,response to DNA damage stimulus			0.00001	1640.65	A=135, G=166		A=63/72, G=78/88	1	
chr3:178952085	A/G	A	SNV		PIK3CA	exonic	1	Hotspot	Gain-of-function			HS	COSM249874;COSM775;COSM776		C=0.00, G=29.73, T=0.00	p.His1047Arg		370	A=0.7027, C=0.0, G=0.2973, T=0.0		Present				+	21	NM_006218.2	c.3140A>G	missense	2.33	0.01	29.0	0.639	PI3-kinase family,Phosphatidylinositol 3- and 4-kinase,Phosphoinositide 3-kinase C2,Phosphoinositide 3-kinase family	rs121913279							1-phosphatidylinositol-3-kinase activity,ATP binding,T cell costimulation,T cell receptor signaling pathway,angiogenesis,anti-apoptosis,blood coagulation,cytosol,epidermal growth factor receptor signaling pathway,fibroblast growth factor receptor signaling pathway,glucose metabolic process,hypomethylation of CpG island,insulin receptor signaling pathway,insulin receptor substrate binding,kinase activity,lamellipodium,leukocyte migration,nerve growth factor receptor signaling pathway,nucleotide binding,phosphatidylinositol 3-kinase complex,phosphatidylinositol phosphorylation,phosphatidylinositol-4,5-bisphosphate 3-kinase activity,phosphatidylinositol-mediated signaling,phosphotransferase activity, alcohol group as acceptor,platelet activation,positive regulation of peptidyl-serine phosphorylation,protein binding,protein kinase B signaling cascade,protein kinase activator activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of multicellular organism growth,signal transduction	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-(METHYLOXY)METHYL-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO4,3,2-DEINDENO4,5-H2BENZOPYRAN-11-YL ACETATE	other	0.00001	674.351	A=260, C=0, G=110, T=0		A=96/164, C=0/0, G=51/59, T=0/0	1,1,1	
chr4:1807894	A/A	G	SNV		FGFR3	exonic	1								100.00	p.(=)		1994	G=0.0, A=1.0		Present				+	14	NM_000142.4	c.1953G>A	synonymous	0.05				Immunoglobulin I-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs7688609		0.042 (ref)	8.0E-4	0.131	0.0449	YES	ATP binding,JAK-STAT cascade,MAPKKK cascade,bone maturation,bone morphogenesis,chondrocyte differentiation,chondrocyte proliferation,cytoplasmic membrane-bounded vesicle,endochondral bone growth,endochondral ossification,endoplasmic reticulum,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor-activated receptor activity,focal adhesion,insulin receptor signaling pathway,integral to plasma membrane,negative regulation of developmental growth,nucleotide binding,peptidyl-tyrosine phosphorylation,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of MAPKKK cascade,positive regulation of cell proliferation,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phospholipase activity,positive regulation of tyrosine phosphorylation of Stat1 protein,positive regulation of tyrosine phosphorylation of Stat3 protein,protein autophosphorylation,protein binding,protein tyrosine kinase activity,receptor activity,regulation of apoptotic process,skeletal system development	Palifermin,Pazopanib		0.00001	30255.0	G=0, A=1994		G=0/0, A=1041/953	1	
chr4:55141051	GCCCGGATGGACATGA/GCCCGGATGGACATGA	GCCCAGATGGACATGA	SNV		PDGFRA	exonic	1					HS	COSM12418		G=0.00, GCCCGGATGGACATGA=100.00	p.(=)		453	GCCCAGATGGACATGA=0.0, G=0.0, GCCCGGATGGACATGA=1.0		Present				+	12	NM_006206.4	c.1701A>G	synonymous	2.79,2.74,2.74,2.74,-5.31,2.74,2.21,0.99,2.74,2.74,0.41,2.64,2.31,-0.28,1.57,2.31				Immunoglobulin I-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs121913270,rs121913271,rs1873778,rs201503614		0.037				YES	ATP binding,Leydig cell differentiation,adrenal gland development,cardiac myofibril assembly,cell activation,cell chemotaxis,cellular response to amino acid stimulus,cytoplasm,elevation of cytosolic calcium ion concentration,embryonic cranial skeleton morphogenesis,embryonic digestive tract morphogenesis,embryonic skeletal system morphogenesis,estrogen metabolic process,extracellular matrix organization,face morphogenesis,female gonad development,gliogenesis,growth factor binding,in utero embryonic development,inner ear development,integral to plasma membrane,intrinsic to plasma membrane,lung development,luteinization,male genitalia development,metanephric glomerular capillary formation,multicellular organismal development,negative regulation of platelet activation,nucleotide binding,nucleus,odontogenesis of dentin-containing tooth,palate development,peptidyl-tyrosine phosphorylation,phosphatidylinositol 3-kinase binding,phosphatidylinositol-mediated signaling,plasma membrane,platelet aggregation,platelet-derived growth factor alpha-receptor activity,platelet-derived growth factor binding,platelet-derived growth factor receptor binding,platelet-derived growth factor receptor signaling pathway,platelet-derived growth factor receptor-alpha signaling pathway,positive regulation of DNA replication,positive regulation of ERK1 and ERK2 cascade,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of fibroblast proliferation,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of phospholipase C activity,protein autophosphorylation,protein homodimerization activity,protein tyrosine kinase activity,receptor activity,regulation of actin cytoskeleton reorganization,regulation of chemotaxis,regulation of mesenchymal stem cell differentiation,response to cytokine stimulus,response to estradiol stimulus,response to hormone stimulus,response to hyperoxia,response to inorganic substance,retina vasculature development in camera-type eye,signal transduction involved in regulation of gene expression,transmembrane receptor protein tyrosine kinase activity,vascular endothelial growth factor receptor signaling pathway,vascular endothelial growth factor-activated receptor activity,wound healing	Becaplermin,Imatinib,Pazopanib,Sunitinib		0.00001	6437.75	GCCCAGATGGACATGA=0, G=0, GCCCGGATGGACATGA=453		GCCCAGATGGACATGA=0/0, G=0/0, GCCCGGATGGACATGA=223/230	3,1	
chr4:153244280	G/A	G	SNV		FBXW7	exonic	1								25.18	p.Ala626Val		556	G=0.7482, A=0.2518		Present				-	12	NM_033632.3	c.1877C>T	missense	2.68	0.0	64.0	1.0	F-box domain,WD domain								Golgi apparatus,SCF ubiquitin ligase complex,SCF-dependent proteasomal ubiquitin-dependent protein catabolic process,cellular response to UV,cytoplasm,endoplasmic reticulum,interspecies interaction between organisms,lipid homeostasis,negative regulation of DNA endoreduplication,negative regulation of Notch signaling pathway,negative regulation of SREBP-mediated signaling pathway,negative regulation of hepatocyte proliferation,negative regulation of triglyceride biosynthetic process,nucleolus,nucleoplasm,nucleus,perinuclear region of cytoplasm,positive regulation of ERK1 and ERK2 cascade,positive regulation of epidermal growth factor-activated receptor activity,positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process,protein binding,protein complex,protein stabilization,protein ubiquitination,regulation of lipid storage,regulation of protein localization,response to DNA damage stimulus,sequence-specific DNA binding transcription factor activity,sister chromatid cohesion,vasculature development			0.00001	837.99	G=416, A=140		G=199/217, A=67/73	1	
chr5:1294086	C/T	C	SNV		TERT	exonic	1								47.65	p.(=)		1998	C=0.5235, T=0.4765		Present				-	2	NM_198253.2	c.915G>A	synonymous	-1.35					rs2736098		0.213 (ref)	0.2597	0.1051	0.2075	YES	DNA binding,DNA strand elongation,PML body,anti-apoptosis,chromosome,chromosome, telomeric region,cytoplasm,metal ion binding,nuclear telomere cap complex,nucleolus,nucleoplasm,nucleotidyltransferase activity,nucleus,protein binding,protein homodimerization activity,replicative senescence,telomerase activity,telomerase holoenzyme complex,telomere formation via telomerase,telomere maintenance,telomere maintenance via telomerase,telomeric DNA binding,telomeric RNA binding,telomeric template RNA reverse transcriptase activity,transferase activity		non-pathogenic	0.00001	8687.82	C=1046, T=952		C=465/581, T=423/529	3	
chr5:38955796	A/A	G	SNV		RICTOR	exonic	1								100.00	p.Ser837Phe		207	G=0.0, A=1.0		Present				-	26	NM_152756.4	c.2510C>T	missense	1.26	0.7	155.0	0.002		rs2043112		0.392 (ref)	0.401	0.2853	0.3618	YES	T cell costimulation,TORC2 complex,actin cytoskeleton reorganization,cytosol,embryo development,fibroblast growth factor receptor signaling pathway,nerve growth factor receptor signaling pathway,phosphatidylinositol-mediated signaling,positive regulation of TOR signaling cascade,positive regulation of actin filament polymerization,positive regulation of peptidyl-tyrosine phosphorylation,protein binding,regulation of Rac GTPase activity,regulation of actin cytoskeleton organization,regulation of protein kinase B signaling cascade,ribosome binding			0.00001	3062.54	G=0, A=207		G=0/0, A=109/98	2	
chr5:67593375	C/T	C	SNV		PIK3R1	exonic	1								25.80	p.(=)		1721	C=0.742, T=0.258		Present				+	16	NM_181523.2	c.2121C>T	synonymous	-0.4				RhoGAP domain,SH2 domain,SH3 domain								1-phosphatidylinositol binding,1-phosphatidylinositol-4-phosphate 3-kinase, class IA complex,ErbB-3 class receptor binding,T cell costimulation,T cell receptor signaling pathway,blood coagulation,cytosol,epidermal growth factor receptor signaling pathway,fibroblast growth factor receptor signaling pathway,growth hormone receptor signaling pathway,insulin binding,insulin receptor binding,insulin receptor signaling pathway,insulin receptor substrate binding,insulin-like growth factor receptor binding,insulin-like growth factor receptor signaling pathway,interspecies interaction between organisms,intracellular,leukocyte migration,nerve growth factor receptor signaling pathway,neurotrophin TRKA receptor binding,phosphatidylinositol 3-kinase cascade,phosphatidylinositol 3-kinase regulator activity,phosphatidylinositol phosphorylation,phosphatidylinositol-4,5-bisphosphate 3-kinase activity,phosphatidylinositol-mediated signaling,platelet activation,positive regulation of establishment of protein localization in plasma membrane,positive regulation of glucose import,protein binding,protein phosphatase binding,signal transduction	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-(METHYLOXY)METHYL-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO4,3,2-DEINDENO4,5-H2BENZOPYRAN-11-YL ACETATE,Isoproterenol		0.00001	2695.69	C=1277, T=444		C=676/601, T=233/211	1	
chr5:131893070	G/A	G	SNV		RAD50	exonic	1								4.93	p.(=)		142	G=0.9507, A=0.0493		Present				+	1	NM_005732.3	c.54G>A	synonymous	2.7				ABC transporter,Rad50 zinc hook motif,RecF/RecN/SMC N terminal domain								3'-5' exonuclease activity,ATP binding,ATP-dependent DNA helicase activity,DNA binding,DNA duplex unwinding,DNA recombination,DNA repair,Mre11 complex,cell cycle,chromosome,double-strand break repair,double-strand break repair via homologous recombination,hydrolase activity,meiosis,metal ion binding,nuclear chromosome, telomeric region,nuclease activity,nucleoplasm,nucleotide binding,positive regulation of kinase activity,positive regulation of protein autophosphorylation,pronucleus,protein binding,protein binding, bridging,reciprocal meiotic recombination,regulation of mitotic recombination,single-stranded DNA specific endodeoxyribonuclease activity,telomere maintenance,telomere maintenance via telomerase,zinc ion binding			0.0683	11.6558	G=135, A=7		G=58/77, A=5/2	2	
chr5:176519419	C/T	C	SNV		FGFR4	exonic	1								8.02	p.(=)		1807	C=0.9198, T=0.0802		Present				+	7	NM_213647.1	c.825C>T	synonymous	-0.86				Immunoglobulin I-set domain,Immunoglobulin V-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs11954456							ATP binding,alveolar secondary septum development,cell migration,cell-cell junction,cytoplasm,endoplasmic reticulum,endosome,extracellular region,fibroblast growth factor 1 binding,fibroblast growth factor 2 binding,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor-activated receptor activity,glucose homeostasis,heparin binding,insulin receptor signaling pathway,integral to plasma membrane,lung development,nucleolus,nucleotide binding,nucleus,organ induction,peptidyl-tyrosine phosphorylation,phosphate ion homeostasis,plasma membrane,positive regulation of DNA biosynthetic process,positive regulation of ERK1 and ERK2 cascade,positive regulation of cell proliferation,positive regulation of metalloenzyme activity,positive regulation of proteolysis,protein autophosphorylation,protein tyrosine kinase activity,receptor activity,regulation of bile acid biosynthetic process,regulation of cholesterol homeostasis,regulation of extracellular matrix disassembly,regulation of lipid metabolic process	Palifermin		0.00001	255.634	C=1662, T=145		C=795/867, T=73/72	1	
chr6:41903782	AG/CA	AG	MNV		CCND3	exonic	2								50.61	p.Ser259Ala		1980	AG=0.4939, CA=0.5061		Present				-	5	NM_001760.4	c.774_775delCTinsTG	synonymous, missense	-0.25,-2.53	0.59	99.0	0.0	Cyclin	rs1051130,rs3218102		0.035,0.415	0.4535	0.2238	0.3757	YES	T cell proliferation,cell division,cyclin-dependent protein kinase activity,cyclin-dependent protein kinase holoenzyme complex,cytoplasm,membrane,nucleus,positive regulation of cyclin-dependent protein kinase activity,positive regulation of protein phosphorylation,protein binding,protein kinase binding,regulation of cell cycle,signal transduction			0.00001	9482.01	AG=978, CA=1002		AG=438/540, CA=397/605	1	
chr6:117622184	G/C	G	SNV		ROS1	exonic	1								42.96	p.Ser2229Cys		284	G=0.5704, C=0.4296		Present				-	42	NM_002944.2	c.6686C>G	missense	0.09	1.0	112.0	0.0	Fibronectin type III domain,Protein kinase domain,Protein tyrosine kinase	rs619203		0.16 (ref)	0.2598	0.0742	0.1969	YES	ATP binding,cell differentiation,cell growth,cell proliferation,columnar/cuboidal epithelial cell development,integral to membrane,membrane fraction,negative regulation of gene expression,nucleotide binding,plasma membrane,protein phosphatase binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of ERK1 and ERK2 cascade,regulation of TOR signaling cascade,regulation of phosphate transport,spermatogenesis,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	1027.81	G=162, C=122		G=85/77, C=52/70	2	
chr6:117622188	T/G	T	SNV		ROS1	exonic	1								43.31	p.Lys2228Gln		284	T=0.5669, G=0.4331		Present				-	42	NM_002944.2	c.6682A>C	missense	1.45	0.36	53.0	0.0	Fibronectin type III domain,Protein kinase domain,Protein tyrosine kinase	rs529156		0.16 (ref)	0.2598	0.0742	0.1969	YES	ATP binding,cell differentiation,cell growth,cell proliferation,columnar/cuboidal epithelial cell development,integral to membrane,membrane fraction,negative regulation of gene expression,nucleotide binding,plasma membrane,protein phosphatase binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of ERK1 and ERK2 cascade,regulation of TOR signaling cascade,regulation of phosphate transport,spermatogenesis,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	1041.37	T=161, G=123		T=84/77, G=53/70	2	
chr6:117622233	C/T	C	SNV		ROS1	exonic	1								42.86	p.Asp2213Asn		280	C=0.5714, T=0.4286		Present				-	42	NM_002944.2	c.6637G>A	missense	0.75	0.22	23.0	0.009	Fibronectin type III domain,Protein kinase domain,Protein tyrosine kinase	rs529038		0.158	0.2594	0.0688	0.1948	YES	ATP binding,cell differentiation,cell growth,cell proliferation,columnar/cuboidal epithelial cell development,integral to membrane,membrane fraction,negative regulation of gene expression,nucleotide binding,plasma membrane,protein phosphatase binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of ERK1 and ERK2 cascade,regulation of TOR signaling cascade,regulation of phosphate transport,spermatogenesis,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	1008.61	C=160, T=120		C=81/79, T=51/69	2	
chr6:117631431	T/G	T	SNV		ROS1	exonic	1								52.32	p.(=)		1034	T=0.4768, G=0.5232		Present				-	40	NM_002944.2	c.6247A>C	synonymous	1.49				Fibronectin type III domain,Protein kinase domain,Protein tyrosine kinase	rs552183		0.138 (ref)	0.1335	0.1405	0.1359	YES	ATP binding,cell differentiation,cell growth,cell proliferation,columnar/cuboidal epithelial cell development,integral to membrane,membrane fraction,negative regulation of gene expression,nucleotide binding,plasma membrane,protein phosphatase binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of ERK1 and ERK2 cascade,regulation of TOR signaling cascade,regulation of phosphate transport,spermatogenesis,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	5226.65	T=493, G=541		T=241/252, G=255/286	1	
chr6:152129077	T/C	T	SNV		ESR1	exonic	1								51.25	p.(=)		837	T=0.4875, C=0.5125		Present				+	2	NM_001122740.1	c.30T>C	synonymous	-1.28				Ligand-binding domain of nuclear hormone receptor,Oestrogen receptor,Zinc finger	rs2077647		0.432 (ref)	0.4769	0.4828	0.4789	YES	Sertoli cell proliferation,T-tubule,androgen metabolic process,antral ovarian follicle growth,beta-catenin binding,cellular response to estrogen stimulus,chromatin binding,chromatin remodeling complex,cytoplasm,enzyme binding,epithelial cell development,epithelial cell proliferation involved in mammary gland duct elongation,estrogen receptor activity,estrogen response element binding,gene expression,hormone binding,intracellular estrogen receptor signaling pathway,mammary gland alveolus development,mammary gland branching involved in pregnancy,membrane,metal ion binding,mitochondrial part,neuron projection,neuroprotection,nitric-oxide synthase regulator activity,nucleoplasm,nucleus,osteoblast development,perikaryon,perinuclear region of cytoplasm,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of epidermal growth factor receptor signaling pathway,positive regulation of fibroblast proliferation,positive regulation of retinoic acid receptor signaling pathway,positive regulation of survival gene product expression,positive regulation of transcription from RNA polymerase II promoter,prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,prostate epithelial cord elongation,protein binding,protein complex binding,receptor activity,regulation of apoptotic process,regulation of branching involved in prostate gland morphogenesis,regulation of transcription, DNA-dependent,response to estradiol stimulus,response to estrogen stimulus,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,signal transduction,steroid binding,steroid hormone mediated signaling pathway,steroid hormone receptor activity,terminal button,transcription factor binding,transcription, DNA-dependent,type 1 metabotropic glutamate receptor binding,uterus development,vagina development,zinc ion binding	(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-4-(2-PYRROLIDIN-1-YLETHOXY)PHENYLCHROMAN-6-OL,(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-9-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(9ALPHA,13BETA,17BETA)-2-(1Z)-BUT-1-EN-1-YLESTRA-1,3,5(10)-TRIENE-3,17-DIOL,(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL,1-4-(Octahydro-Pyrido1,2-aPyrazin-2-Yl)-Phenyl-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,17-METHYL-17-ALPHA-DIHYDROEQUILENIN,2-AMINO-1-METHYL-6-PHENYLIMIDAZO4,5-BPYRIDINE,2-Phenyl-1-4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,4-(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(2-amino-1-methyl-1H-imidazo4,5-bpyridin-6-yl)phenol,4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL,4-1-allyl-7-(trifluoromethyl)-1H-indazol-3-ylbenzene-1,3-diol,5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YLACETONITRILE,Allylestrenol,Chlorotrianisene,Clomifene,Compound 18,Compound 19,Compound 4-D,Conjugated Estrogens,DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO2.2.1HEPT-5-ENE-2,3-DICARBOXYLATE,Danazol,Desogestrel,Dienestrol,Diethylstilbestrol,Estradiol,Estramustine,Estriol,Estrone,Estropipate,Ethinyl Estradiol,Ethynodiol Diacetate,Etonogestrel,Fluoxymesterone,Fulvestrant,Genistein,Levonorgestrel,Medroxyprogesterone,Melatonin,Mestranol,N-(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE,Naloxone,Norgestimate,Progesterone,Quinestrol,RALOXIFENE CORE,Raloxifene,Tamoxifen,Toremifene,Trilostane,dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo2.2.1hepta-2,5-diene-2,3-dicarboxylate		0.00001	4099.42	T=408, C=429		T=228/180, C=241/188	1	
chr6:152201875	C/C	T	SNV		ESR1	exonic	1								100.00	p.(=)		183	T=0.0, C=1.0		Present				+	4	NM_001122740.1	c.729T>C	synonymous	0.22				Ligand-binding domain of nuclear hormone receptor,Oestrogen receptor,Zinc finger	rs4986934		0.018 (ref)	0.04	0.0082	0.0292	YES	Sertoli cell proliferation,T-tubule,androgen metabolic process,antral ovarian follicle growth,beta-catenin binding,cellular response to estrogen stimulus,chromatin binding,chromatin remodeling complex,cytoplasm,enzyme binding,epithelial cell development,epithelial cell proliferation involved in mammary gland duct elongation,estrogen receptor activity,estrogen response element binding,gene expression,hormone binding,intracellular estrogen receptor signaling pathway,mammary gland alveolus development,mammary gland branching involved in pregnancy,membrane,metal ion binding,mitochondrial part,neuron projection,neuroprotection,nitric-oxide synthase regulator activity,nucleoplasm,nucleus,osteoblast development,perikaryon,perinuclear region of cytoplasm,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of epidermal growth factor receptor signaling pathway,positive regulation of fibroblast proliferation,positive regulation of retinoic acid receptor signaling pathway,positive regulation of survival gene product expression,positive regulation of transcription from RNA polymerase II promoter,prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,prostate epithelial cord elongation,protein binding,protein complex binding,receptor activity,regulation of apoptotic process,regulation of branching involved in prostate gland morphogenesis,regulation of transcription, DNA-dependent,response to estradiol stimulus,response to estrogen stimulus,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,signal transduction,steroid binding,steroid hormone mediated signaling pathway,steroid hormone receptor activity,terminal button,transcription factor binding,transcription, DNA-dependent,type 1 metabotropic glutamate receptor binding,uterus development,vagina development,zinc ion binding	(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-4-(2-PYRROLIDIN-1-YLETHOXY)PHENYLCHROMAN-6-OL,(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-9-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(9ALPHA,13BETA,17BETA)-2-(1Z)-BUT-1-EN-1-YLESTRA-1,3,5(10)-TRIENE-3,17-DIOL,(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL,1-4-(Octahydro-Pyrido1,2-aPyrazin-2-Yl)-Phenyl-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,17-METHYL-17-ALPHA-DIHYDROEQUILENIN,2-AMINO-1-METHYL-6-PHENYLIMIDAZO4,5-BPYRIDINE,2-Phenyl-1-4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,4-(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(2-amino-1-methyl-1H-imidazo4,5-bpyridin-6-yl)phenol,4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL,4-1-allyl-7-(trifluoromethyl)-1H-indazol-3-ylbenzene-1,3-diol,5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YLACETONITRILE,Allylestrenol,Chlorotrianisene,Clomifene,Compound 18,Compound 19,Compound 4-D,Conjugated Estrogens,DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO2.2.1HEPT-5-ENE-2,3-DICARBOXYLATE,Danazol,Desogestrel,Dienestrol,Diethylstilbestrol,Estradiol,Estramustine,Estriol,Estrone,Estropipate,Ethinyl Estradiol,Ethynodiol Diacetate,Etonogestrel,Fluoxymesterone,Fulvestrant,Genistein,Levonorgestrel,Medroxyprogesterone,Melatonin,Mestranol,N-(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE,Naloxone,Norgestimate,Progesterone,Quinestrol,RALOXIFENE CORE,Raloxifene,Tamoxifen,Toremifene,Trilostane,dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo2.2.1hepta-2,5-diene-2,3-dicarboxylate		0.00001	2739.13	T=0, C=183		T=0/0, C=60/123	1	
chr6:152265522	G/C	G	SNV		ESR1	exonic	1								47.41	p.(=)		926	G=0.5259, C=0.4741		Present				+	5	NM_001122740.1	c.975G>C	synonymous	-0.42				Ligand-binding domain of nuclear hormone receptor,Oestrogen receptor,Zinc finger	rs1801132		0.262 (ref)	0.2257	0.1074	0.1856	YES	Sertoli cell proliferation,T-tubule,androgen metabolic process,antral ovarian follicle growth,beta-catenin binding,cellular response to estrogen stimulus,chromatin binding,chromatin remodeling complex,cytoplasm,enzyme binding,epithelial cell development,epithelial cell proliferation involved in mammary gland duct elongation,estrogen receptor activity,estrogen response element binding,gene expression,hormone binding,intracellular estrogen receptor signaling pathway,mammary gland alveolus development,mammary gland branching involved in pregnancy,membrane,metal ion binding,mitochondrial part,neuron projection,neuroprotection,nitric-oxide synthase regulator activity,nucleoplasm,nucleus,osteoblast development,perikaryon,perinuclear region of cytoplasm,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of epidermal growth factor receptor signaling pathway,positive regulation of fibroblast proliferation,positive regulation of retinoic acid receptor signaling pathway,positive regulation of survival gene product expression,positive regulation of transcription from RNA polymerase II promoter,prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,prostate epithelial cord elongation,protein binding,protein complex binding,receptor activity,regulation of apoptotic process,regulation of branching involved in prostate gland morphogenesis,regulation of transcription, DNA-dependent,response to estradiol stimulus,response to estrogen stimulus,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,signal transduction,steroid binding,steroid hormone mediated signaling pathway,steroid hormone receptor activity,terminal button,transcription factor binding,transcription, DNA-dependent,type 1 metabotropic glutamate receptor binding,uterus development,vagina development,zinc ion binding	(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-4-(2-PYRROLIDIN-1-YLETHOXY)PHENYLCHROMAN-6-OL,(3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-9-OL,(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTACCHROMEN-8-OL,(9ALPHA,13BETA,17BETA)-2-(1Z)-BUT-1-EN-1-YLESTRA-1,3,5(10)-TRIENE-3,17-DIOL,(9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL,1-4-(Octahydro-Pyrido1,2-aPyrazin-2-Yl)-Phenyl-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,17-METHYL-17-ALPHA-DIHYDROEQUILENIN,2-AMINO-1-METHYL-6-PHENYLIMIDAZO4,5-BPYRIDINE,2-Phenyl-1-4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol,3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL,4-(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO3.3.1NON-7-EN-2-YLPHENOL,4-(2-amino-1-methyl-1H-imidazo4,5-bpyridin-6-yl)phenol,4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL,4-1-allyl-7-(trifluoromethyl)-1H-indazol-3-ylbenzene-1,3-diol,5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YLACETONITRILE,Allylestrenol,Chlorotrianisene,Clomifene,Compound 18,Compound 19,Compound 4-D,Conjugated Estrogens,DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO2.2.1HEPT-5-ENE-2,3-DICARBOXYLATE,Danazol,Desogestrel,Dienestrol,Diethylstilbestrol,Estradiol,Estramustine,Estriol,Estrone,Estropipate,Ethinyl Estradiol,Ethynodiol Diacetate,Etonogestrel,Fluoxymesterone,Fulvestrant,Genistein,Levonorgestrel,Medroxyprogesterone,Melatonin,Mestranol,N-(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE,Naloxone,Norgestimate,Progesterone,Quinestrol,RALOXIFENE CORE,Raloxifene,Tamoxifen,Toremifene,Trilostane,dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo2.2.1hepta-2,5-diene-2,3-dicarboxylate		0.00001	3821.11	G=487, C=439		G=268/219, C=223/216	1	
chr7:6026775	C/C	T	SNV		PMS2	exonic	1								100.00	p.Lys541Glu		1631	T=0.0, C=1.0		Present				-	11	NM_000535.5	c.1621A>G	missense	0.74	1.0	56.0	0.0	DNA mismatch repair protein,Histidine kinase-	rs2228006		0.121 (ref)	0.1543	0.0815	0.1296	YES	ATP binding,ATP catabolic process,ATPase activity,DNA binding,MutLalpha complex,MutSalpha complex binding,endonuclease activity,hydrolase activity,mismatch repair,mismatched DNA binding,nucleus,protein binding,reciprocal meiotic recombination,response to drug,single base insertion or deletion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments	Adenosine-5'-Diphosphate,Phosphothiophosphoric Acid-Adenylate Ester		0.00001	24501.9	T=0, C=1631		T=0/0, C=808/823	4	
chr7:6026942	G/T	G	SNV		PMS2	exonic	1								56.88	p.Thr485Lys		1199	G=0.4312, T=0.5688		Present				-	11	NM_000535.5	c.1454C>A	missense	-1.91	0.9	78.0	0.0	DNA mismatch repair protein,Histidine kinase-	rs1805323		0.113 (ref)	0.0407	0.0195	0.0335	YES	ATP binding,ATP catabolic process,ATPase activity,DNA binding,MutLalpha complex,MutSalpha complex binding,endonuclease activity,hydrolase activity,mismatch repair,mismatched DNA binding,nucleus,protein binding,reciprocal meiotic recombination,response to drug,single base insertion or deletion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments	Adenosine-5'-Diphosphate,Phosphothiophosphoric Acid-Adenylate Ester		0.00001	6870.27	G=517, T=682		G=250/267, T=339/343	1	
chr7:6026988	G/A	G	SNV		PMS2	exonic	1								41.16	p.Pro470Ser		1861	G=0.5884, A=0.4116		Present				-	11	NM_000535.5	c.1408C>T	missense	0.39	0.51	74.0	0.002	DNA mismatch repair protein,Histidine kinase-	rs1805321		0.394 (ref)	0.4209	0.2819	0.3738	YES	ATP binding,ATP catabolic process,ATPase activity,DNA binding,MutLalpha complex,MutSalpha complex binding,endonuclease activity,hydrolase activity,mismatch repair,mismatched DNA binding,nucleus,protein binding,reciprocal meiotic recombination,response to drug,single base insertion or deletion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments	Adenosine-5'-Diphosphate,Phosphothiophosphoric Acid-Adenylate Ester	non-pathogenic	0.00001	6364.02	G=1095, A=766		G=549/546, A=351/415	2	
chr7:6036980	C/C	G	SNV		PMS2	exonic	1								100.00	p.(=)		1847	G=0.0, C=1.0		Present				-	7	NM_000535.5	c.780C>G	synonymous	-5.63				DNA mismatch repair protein,Histidine kinase-	rs1805319		0.157 (ref)	0.1852	0.1586	0.1762	YES	ATP binding,ATP catabolic process,ATPase activity,DNA binding,MutLalpha complex,MutSalpha complex binding,endonuclease activity,hydrolase activity,mismatch repair,mismatched DNA binding,nucleus,protein binding,reciprocal meiotic recombination,response to drug,single base insertion or deletion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments	Adenosine-5'-Diphosphate,Phosphothiophosphoric Acid-Adenylate Ester	non-pathogenic	0.00001	27894.6	G=0, C=1847		G=0/0, C=987/860	2	
chr7:6043386	G/A	G	SNV		PMS2	exonic	1								92.11	p.(=)		38	G=0.0789, A=0.9211		Present				-	4	NM_000535.5	c.288C>T	synonymous	-0.41				DNA mismatch repair protein,Histidine kinase-	rs12532895		0.113 (ref)	0.0277	0.019	0.0245	YES	ATP binding,ATP catabolic process,ATPase activity,DNA binding,MutLalpha complex,MutSalpha complex binding,endonuclease activity,hydrolase activity,mismatch repair,mismatched DNA binding,nucleus,protein binding,reciprocal meiotic recombination,response to drug,single base insertion or deletion binding,single-stranded DNA binding,somatic hypermutation of immunoglobulin genes,somatic recombination of immunoglobulin gene segments	Adenosine-5'-Diphosphate,Phosphothiophosphoric Acid-Adenylate Ester	untested	0.00001	492.194	G=3, A=35		G=2/1, A=30/5	2	
chr7:55249063	A/A	G	SNV		EGFR,EGFR-AS1	exonic, exonic_nc	1								100.00	p.(=)		1993	G=0.0, A=1.0		Present				+, -	20	NM_005228.3, NR_047551.1	c.2361G>A	synonymous	2.8				Furin-like cysteine rich region,Protein kinase domain,Protein tyrosine kinase,Receptor L domain	rs1050171		0.418 (ref)	0.3962	0.4226	0.4576	YES	AP-2 adaptor complex,ATP binding,Golgi apparatus,Golgi membrane,MAP/ERK kinase kinase activity,Shc-EGFR complex,actin filament binding,activation of phospholipase A2 activity by calcium-mediated signaling,activation of phospholipase C activity,axon guidance,basolateral plasma membrane,cell morphogenesis,cell proliferation,cell surface receptor linked signaling pathway,cell-cell adhesion,cerebral cortex cell migration,cytoplasm,digestive tract morphogenesis,double-stranded DNA binding,embryonic placenta development,endocytic vesicle,endoplasmic reticulum,endoplasmic reticulum membrane,endosome,endosome membrane,enzyme binding,epidermal growth factor receptor signaling pathway,epidermal growth factor-activated receptor activity,extracellular region,extracellular space,hair follicle development,identical protein binding,integral to membrane,intracellular,membrane,membrane raft,morphogenesis of an epithelial fold,multicellular organismal development,negative regulation of apoptotic process,negative regulation of epidermal growth factor receptor signaling pathway,negative regulation of protein catabolic process,nitric-oxide synthase regulator activity,nuclear membrane,nucleotide binding,nucleus,ossification,perinuclear region of cytoplasm,plasma membrane,positive regulation of DNA repair,positive regulation of DNA replication,positive regulation of MAP kinase activity,positive regulation of catenin import into nucleus,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of cyclin-dependent protein kinase activity involved in G1/S,positive regulation of epithelial cell proliferation,positive regulation of fibroblast proliferation,positive regulation of nitric oxide biosynthetic process,positive regulation of phosphorylation,positive regulation of protein kinase B signaling cascade,protein autophosphorylation,protein binding,protein heterodimerization activity,protein insertion into membrane,protein phosphatase binding,protein tyrosine kinase activity,receptor activity,receptor signaling protein tyrosine kinase activity,regulation of nitric-oxide synthase activity,regulation of peptidyl-tyrosine phosphorylation,response to UV-A,response to stress,salivary gland morphogenesis,signal transducer activity,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane signaling receptor activity	Cetuximab,Erlotinib,Flavopiridol,Gefitinib,Lapatinib,Lidocaine,N-4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL-ACRYLAMIDE,Panitumumab,S-{3-(4-ANILINOQUINAZOLIN-6-YL)AMINO-3-OXOPROPYL}-L-CYSTEINE,Trastuzumab,ZD-6474		0.00001	30227.6	G=0, A=1993		G=0/0, A=993/1000	1	
chr7:55266417	C/C	T	SNV		EGFR	exonic	1								100.00	p.(=)		519	T=0.0, C=1.0		Present				+	23	NM_005228.3	c.2709T>C	synonymous	-1.92				Furin-like cysteine rich region,Protein kinase domain,Protein tyrosine kinase,Receptor L domain	rs1140475		0.095 (ref)	0.1267	0.0801	0.1109	YES	AP-2 adaptor complex,ATP binding,Golgi apparatus,Golgi membrane,MAP/ERK kinase kinase activity,Shc-EGFR complex,actin filament binding,activation of phospholipase A2 activity by calcium-mediated signaling,activation of phospholipase C activity,axon guidance,basolateral plasma membrane,cell morphogenesis,cell proliferation,cell surface receptor linked signaling pathway,cell-cell adhesion,cerebral cortex cell migration,cytoplasm,digestive tract morphogenesis,double-stranded DNA binding,embryonic placenta development,endocytic vesicle,endoplasmic reticulum,endoplasmic reticulum membrane,endosome,endosome membrane,enzyme binding,epidermal growth factor receptor signaling pathway,epidermal growth factor-activated receptor activity,extracellular region,extracellular space,hair follicle development,identical protein binding,integral to membrane,intracellular,membrane,membrane raft,morphogenesis of an epithelial fold,multicellular organismal development,negative regulation of apoptotic process,negative regulation of epidermal growth factor receptor signaling pathway,negative regulation of protein catabolic process,nitric-oxide synthase regulator activity,nuclear membrane,nucleotide binding,nucleus,ossification,perinuclear region of cytoplasm,plasma membrane,positive regulation of DNA repair,positive regulation of DNA replication,positive regulation of MAP kinase activity,positive regulation of catenin import into nucleus,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of cyclin-dependent protein kinase activity involved in G1/S,positive regulation of epithelial cell proliferation,positive regulation of fibroblast proliferation,positive regulation of nitric oxide biosynthetic process,positive regulation of phosphorylation,positive regulation of protein kinase B signaling cascade,protein autophosphorylation,protein binding,protein heterodimerization activity,protein insertion into membrane,protein phosphatase binding,protein tyrosine kinase activity,receptor activity,receptor signaling protein tyrosine kinase activity,regulation of nitric-oxide synthase activity,regulation of peptidyl-tyrosine phosphorylation,response to UV-A,response to stress,salivary gland morphogenesis,signal transducer activity,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane signaling receptor activity	Cetuximab,Erlotinib,Flavopiridol,Gefitinib,Lapatinib,Lidocaine,N-4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL-ACRYLAMIDE,Panitumumab,S-{3-(4-ANILINOQUINAZOLIN-6-YL)AMINO-3-OXOPROPYL}-L-CYSTEINE,Trastuzumab,ZD-6474		0.00001	7746.28	T=0, C=519		T=0/0, C=297/222	1	
chr7:116435768	C/T	C	SNV		MET	exonic	1								61.59	p.(=)		1984	C=0.3841, T=0.6159		Present				+	20	NM_001127500.1	c.3912C>T	synonymous	-3.37				IPT/TIG domain,Plexin repeat,Protein kinase domain,Protein tyrosine kinase,Sema domain	rs41736		0.372 (ref)	0.4243	0.1041	0.3235	YES	ATP binding,axon guidance,basal plasma membrane,cell proliferation,cell surface receptor linked signaling pathway,hepatocyte growth factor receptor signaling pathway,hepatocyte growth factor-activated receptor activity,integral to membrane,integral to plasma membrane,multicellular organismal development,nucleotide binding,plasma membrane,protein binding,protein tyrosine kinase activity,receptor activity,signal transduction	1-(2-NITROPHENYL)SULFONYL-1H-PYRROLO3,2-BPYRIDINE-6-CARBOXAMIDE,1-(4-fluorophenyl)-N-3-fluoro-4-(1H-pyrrolo2,3-bpyridin-4-yloxy)phenyl-2-oxo-1,2-dihydropyridine-3-carboxamide,2-(4-fluorophenyl)-N-{3-fluoro-4-(1H-pyrrolo2,3-bpyridin-4-yloxy)phenylcarbamoyl}acetamide,3-(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine,3-3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-ylphenol,6-{6-(1-methyl-1H-pyrazol-4-yl)1,2,4triazolo4,3-bpyridazin-3-ylsulfanyl}quinoline,K-252a,N-(3-chlorophenyl)-N-methyl-2-oxo-3-(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl-2H-indole-5-sulfonamide,N-({4-(2-aminopyridin-4-yl)oxy-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide		0.00001	13040.0	C=762, T=1222		C=437/325, T=620/602	1	
chr7:116436022	G/A	G	SNV		MET	exonic	1								61.98	p.(=)		605	G=0.3802, A=0.6198		Present				+	21	NM_001127500.1	c.4071G>A	synonymous	-3.55				IPT/TIG domain,Plexin repeat,Protein kinase domain,Protein tyrosine kinase,Sema domain	rs2023748		0.373 (ref)	0.4268	0.1029	0.3225	YES	ATP binding,axon guidance,basal plasma membrane,cell proliferation,cell surface receptor linked signaling pathway,hepatocyte growth factor receptor signaling pathway,hepatocyte growth factor-activated receptor activity,integral to membrane,integral to plasma membrane,multicellular organismal development,nucleotide binding,plasma membrane,protein binding,protein tyrosine kinase activity,receptor activity,signal transduction	1-(2-NITROPHENYL)SULFONYL-1H-PYRROLO3,2-BPYRIDINE-6-CARBOXAMIDE,1-(4-fluorophenyl)-N-3-fluoro-4-(1H-pyrrolo2,3-bpyridin-4-yloxy)phenyl-2-oxo-1,2-dihydropyridine-3-carboxamide,2-(4-fluorophenyl)-N-{3-fluoro-4-(1H-pyrrolo2,3-bpyridin-4-yloxy)phenylcarbamoyl}acetamide,3-(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine,3-3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-ylphenol,6-{6-(1-methyl-1H-pyrazol-4-yl)1,2,4triazolo4,3-bpyridazin-3-ylsulfanyl}quinoline,K-252a,N-(3-chlorophenyl)-N-methyl-2-oxo-3-(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl-2H-indole-5-sulfonamide,N-({4-(2-aminopyridin-4-yl)oxy-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide		0.00001	3971.47	G=230, A=375		G=126/104, A=211/164	1	
chr7:140453116	A/T	A	SNV		BRAF	exonic	1								40.82	p.Ser607Thr		1994	A=0.5918, T=0.4082		Present				-	15	NM_004333.4	c.1819T>A	missense	2.17	0.0	58.0	0.026	C1-like domain,Phorbol esters/diacylglycerol binding domain (C1 domain),Protein kinase domain,Protein tyrosine kinase,Raf-like Ras-binding domain								ATP binding,MAP kinase kinase kinase activity,activation of MAPKK activity,anti-apoptosis,cytoplasm,cytosol,metal ion binding,mitogen-activated protein kinase kinase binding,negative regulation of apoptotic process,negative regulation of neuron apoptosis,nerve growth factor receptor signaling pathway,nucleotide binding,nucleus,organ morphogenesis,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of peptidyl-serine phosphorylation,protein binding,protein heterodimerization activity,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,receptor signaling protein activity,response to cAMP,response to peptide hormone stimulus,small GTPase mediated signal transduction,soluble fraction,synaptic transmission,synaptosome	(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime,N-{2,4-difluoro-3-(5-pyridin-3-yl-1H-pyrrolo2,3-bpyridin-3-yl)carbonylphenyl}ethanesulfonamide,N-{3-(5-chloro-1H-pyrrolo2,3-bpyridin-3-yl)carbonyl-2,4-difluorophenyl}propane-1-sulfonamide,Sorafenib		0.00001	6747.86	A=1180, T=814		A=547/633, T=403/411	1	
chr7:140453136	ACTG/TCTG	ACTG	SNV		BRAF	exonic	1	Hotspot	Gain-of-function			HS	COSM26504;COSM6137;COSM18443;COSM476;COSM1583011;COSM474;COSM249889;COSM473;COSM1127;COSM1735763		ACTGTAGCTAGACCAAAATCTG=0.00, CCTG=0.00, GCTG=0.00, TCTG=44.04, CGTG=0.00, CTTG=0.00, TGTG=0.00, TTTG=0.00, CTCG=0.00, TTTA=0.00	p.Val600Glu		302	ACTG=0.5596, ACTGTAGCTAGACCAAAATCTG=0.0, CCTG=0.0, GCTG=0.0, TCTG=0.4404, CGTG=0.0, CTTG=0.0, TGTG=0.0, TTTG=0.0, CTCG=0.0, TTTA=0.0		Present				-	15	NM_004333.4	c.1799T>A	missense	2.17,2.69,2.17,2.69	0.0	121.0	0.971	C1-like domain,Phorbol esters/diacylglycerol binding domain (C1 domain),Protein kinase domain,Protein tyrosine kinase,Raf-like Ras-binding domain	rs113488022,rs121913227,rs121913374,rs121913375,rs121913377,rs121913378							ATP binding,MAP kinase kinase kinase activity,activation of MAPKK activity,anti-apoptosis,cytoplasm,cytosol,metal ion binding,mitogen-activated protein kinase kinase binding,negative regulation of apoptotic process,negative regulation of neuron apoptosis,nerve growth factor receptor signaling pathway,nucleotide binding,nucleus,organ morphogenesis,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of peptidyl-serine phosphorylation,protein binding,protein heterodimerization activity,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,receptor signaling protein activity,response to cAMP,response to peptide hormone stimulus,small GTPase mediated signal transduction,soluble fraction,synaptic transmission,synaptosome	(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime,N-{2,4-difluoro-3-(5-pyridin-3-yl-1H-pyrrolo2,3-bpyridin-3-yl)carbonylphenyl}ethanesulfonamide,N-{3-(5-chloro-1H-pyrrolo2,3-bpyridin-3-yl)carbonyl-2,4-difluorophenyl}propane-1-sulfonamide,Sorafenib	other,pathogenic	0.00001	1060.63	ACTG=169, ACTGTAGCTAGACCAAAATCTG=0, CCTG=0, GCTG=0, TCTG=133, CGTG=0, CTTG=0, TGTG=0, TTTG=0, CTCG=0, TTTA=0		ACTG=81/88, ACTGTAGCTAGACCAAAATCTG=0/0, CCTG=0/0, GCTG=0/0, TCTG=60/73, CGTG=0/0, CTTG=0/0, TGTG=0/0, TTTG=0/0, CTCG=0/0, TTTA=0/0	1,1,1,1,1,1,1,1,1,1	
chr8:90958422	C/C	T	SNV		NBN	exonic	1								97.70	p.(=)		261	T=0.023, C=0.977		Present				-	13	NM_002485.4	c.2016A>G	synonymous	-1.06				BRCA1 C Terminus (BRCT) domain,DNA damage repair protein Nbs1,FHA domain	rs1061302		0.328 (ref)	0.3132	0.2276	0.2842	YES	ATP-dependent DNA helicase activity,DNA damage checkpoint,DNA damage response, signal transduction by p53 class mediator,DNA duplex unwinding,DNA repair,G2/M transition checkpoint,Mre11 complex,apoptotic process,blastocyst growth,cell cycle,cell cycle arrest,chromosome,damaged DNA binding,double-strand break repair,double-strand break repair via homologous recombination,in utero embryonic development,intracellular,isotype switching,meiosis,mitotic cell cycle G1/S transition checkpoint,mitotic cell cycle G2/M transition DNA damage checkpoint,negative regulation of neuron differentiation,neuromuscular process controlling balance,nuclear chromosome, telomeric region,nuclear inclusion body,nucleolus,nucleoplasm,nucleus,positive regulation of cell proliferation,positive regulation of kinase activity,positive regulation of protein autophosphorylation,protein N-terminus binding,protein binding,regulation of DNA-dependent DNA replication initiation,regulation of fibroblast proliferation,replication fork,response to drug,telomere maintenance,transcription factor binding			0.00001	3721.6	T=6, C=255		T=3/3, C=132/123	1	
chr8:90967711	G/G	A	SNV		NBN	exonic	1								100.00	p.(=)		648	A=0.0, G=1.0		Present				-	10	NM_002485.4	c.1197T>C	synonymous	-0.48				BRCA1 C Terminus (BRCT) domain,DNA damage repair protein Nbs1,FHA domain	rs709816		0.424 (ref)	0.3559	0.2473	0.4903	YES	ATP-dependent DNA helicase activity,DNA damage checkpoint,DNA damage response, signal transduction by p53 class mediator,DNA duplex unwinding,DNA repair,G2/M transition checkpoint,Mre11 complex,apoptotic process,blastocyst growth,cell cycle,cell cycle arrest,chromosome,damaged DNA binding,double-strand break repair,double-strand break repair via homologous recombination,in utero embryonic development,intracellular,isotype switching,meiosis,mitotic cell cycle G1/S transition checkpoint,mitotic cell cycle G2/M transition DNA damage checkpoint,negative regulation of neuron differentiation,neuromuscular process controlling balance,nuclear chromosome, telomeric region,nuclear inclusion body,nucleolus,nucleoplasm,nucleus,positive regulation of cell proliferation,positive regulation of kinase activity,positive regulation of protein autophosphorylation,protein N-terminus binding,protein binding,regulation of DNA-dependent DNA replication initiation,regulation of fibroblast proliferation,replication fork,response to drug,telomere maintenance,transcription factor binding			0.00001	9714.06	A=0, G=648		A=0/0, G=386/262	1	
chr8:90990479	G/G	C	SNV		NBN	exonic	1								100.00	p.Glu185Gln		278	C=0.0, G=1.0		Present				-	5	NM_002485.4	c.553G>C	missense	0.09	1.0	29.0	0.0	BRCA1 C Terminus (BRCT) domain,DNA damage repair protein Nbs1,FHA domain	rs1805794		0.333 (ref)	0.3136	0.2338	0.2866	YES	ATP-dependent DNA helicase activity,DNA damage checkpoint,DNA damage response, signal transduction by p53 class mediator,DNA duplex unwinding,DNA repair,G2/M transition checkpoint,Mre11 complex,apoptotic process,blastocyst growth,cell cycle,cell cycle arrest,chromosome,damaged DNA binding,double-strand break repair,double-strand break repair via homologous recombination,in utero embryonic development,intracellular,isotype switching,meiosis,mitotic cell cycle G1/S transition checkpoint,mitotic cell cycle G2/M transition DNA damage checkpoint,negative regulation of neuron differentiation,neuromuscular process controlling balance,nuclear chromosome, telomeric region,nuclear inclusion body,nucleolus,nucleoplasm,nucleus,positive regulation of cell proliferation,positive regulation of kinase activity,positive regulation of protein autophosphorylation,protein N-terminus binding,protein binding,regulation of DNA-dependent DNA replication initiation,regulation of fibroblast proliferation,replication fork,response to drug,telomere maintenance,transcription factor binding			0.00001	4142.02	C=0, G=278		C=0/0, G=153/125	1	
chr8:90995019	T/T	C	SNV		NBN	exonic	1								100.00	p.(=)		1999	C=0.0, T=1.0		Present				-	2	NM_002485.4	c.102G>A	synonymous	-0.39				BRCA1 C Terminus (BRCT) domain,DNA damage repair protein Nbs1,FHA domain	rs1063045		0.35 (ref)	0.3147	0.3103	0.3132	YES	ATP-dependent DNA helicase activity,DNA damage checkpoint,DNA damage response, signal transduction by p53 class mediator,DNA duplex unwinding,DNA repair,G2/M transition checkpoint,Mre11 complex,apoptotic process,blastocyst growth,cell cycle,cell cycle arrest,chromosome,damaged DNA binding,double-strand break repair,double-strand break repair via homologous recombination,in utero embryonic development,intracellular,isotype switching,meiosis,mitotic cell cycle G1/S transition checkpoint,mitotic cell cycle G2/M transition DNA damage checkpoint,negative regulation of neuron differentiation,neuromuscular process controlling balance,nuclear chromosome, telomeric region,nuclear inclusion body,nucleolus,nucleoplasm,nucleus,positive regulation of cell proliferation,positive regulation of kinase activity,positive regulation of protein autophosphorylation,protein N-terminus binding,protein binding,regulation of DNA-dependent DNA replication initiation,regulation of fibroblast proliferation,replication fork,response to drug,telomere maintenance,transcription factor binding			0.00001	30434.5	C=0, T=1999		C=0/0, T=968/1031	1	
chr9:98209594	G/A	G	SNV		PTCH1	exonic	1								85.64	p.Pro1315Leu		1525	G=0.1436, A=0.8564		Present				-	23	NM_000264.3	c.3944C>T	missense	2.51	0.0	98.0	0.906	Patched family	rs357564		0.382 (ref)	0.3298	0.2389	0.2993	YES	Golgi apparatus,brain development,branching involved in ureteric bud morphogenesis,caveola,cell differentiation involved in kidney development,cell proliferation involved in metanephros development,cellular response to cholesterol,cholesterol binding,cyclin binding,dorsal/ventral neural tube patterning,dorsal/ventral pattern formation,embryonic limb morphogenesis,epidermis development,glucose homeostasis,heart morphogenesis,hedgehog family protein binding,heparin binding,hindlimb morphogenesis,integral to plasma membrane,intracellular membrane-bounded organelle,keratinocyte proliferation,limb morphogenesis,mammary gland development,mammary gland duct morphogenesis,mammary gland epithelial cell differentiation,midbody,negative regulation of epithelial cell proliferation,negative regulation of multicellular organism growth,negative regulation of osteoblast differentiation,negative regulation of sequence-specific DNA binding transcription factor activity,negative regulation of smoothened signaling pathway,negative regulation of transcription from RNA polymerase II promoter,neural plate axis specification,neural tube closure,neural tube formation,neural tube patterning,organ morphogenesis,patched binding,pattern specification process,perinuclear region of cytoplasm,pharyngeal system development,plasma membrane,positive regulation of cholesterol efflux,protein binding,protein processing,protein targeting to plasma membrane,receptor activity,regulation of growth,regulation of mitotic cell cycle,regulation of protein localization,regulation of smoothened signaling pathway,renal system development,response to chlorate,signal transduction,smoothened binding,smoothened signaling pathway,somite development			0.00001	17177.9	G=219, A=1306		G=156/63, A=581/725	6	
chr9:135782221	T/C	T	SNV		TSC1	exonic	1								42.25	p.(=)		400	T=0.5775, C=0.4225		Present				-	14	NM_000368.4	c.1335A>G	synonymous	0.43				Hamartin protein	rs7862221		0.14 (ref)	0.1463	0.219	0.1709	YES	GTPase activating protein binding,GTPase regulator activity,TSC1-TSC2 complex,actin filament,activation of Rho GTPase activity,cardiac muscle cell differentiation,cell cortex,cell cycle arrest,cell projection organization,cell-matrix adhesion,cerebral cortex development,chaperone binding,cytoplasm,cytosol,embryo development,growth cone,hippocampus development,insulin receptor signaling pathway,kidney development,lamellipodium,membrane,membrane fraction,microsome,myelination,negative regulation of TOR signaling cascade,negative regulation of cell proliferation,negative regulation of cell size,negative regulation of translation,nervous system development,neural tube closure,positive regulation of focal adhesion assembly,potassium ion transport,protein N-terminus binding,protein binding,protein complex,protein heterooligomerization,protein stabilization,rRNA export from nucleus,regulation of actin cytoskeleton organization,regulation of cell-matrix adhesion,regulation of phosphoprotein phosphatase activity,regulation of protein kinase activity,regulation of stress fiber assembly,regulation of translation,response to insulin stimulus,synapse organization		untested	0.00001	1423.5	T=231, C=169		T=137/94, C=99/70	2	
chr9:139391636	G/A	G	SNV		NOTCH1	exonic	1								49.55	p.(=)		1996	G=0.5045, A=0.4955		Present				-	34	NM_017617.3	c.6555C>T	synonymous	-0.09				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,Laminin EGF-like (Domains III and V),NOTCH protein	rs2229974		0.305 (ref)	0.4467	0.3639	0.4187	YES	Golgi apparatus,Golgi lumen,MAML1-RBP-Jkappa- ICN1 complex,Notch receptor processing,Notch signaling pathway,acrosomal vesicle,anagen,aortic valve morphogenesis,axonogenesis,branching morphogenesis of a tube,calcium ion binding,cell differentiation in spinal cord,cell fate specification,chromatin DNA binding,compartment pattern specification,core promoter binding,cytoplasm,cytosol,determination of left/right symmetry,embryo development,embryonic hindlimb morphogenesis,endoderm development,endoplasmic reticulum lumen,extracellular region,forebrain development,foregut morphogenesis,gene expression,hair follicle morphogenesis,heart development,immune response,in utero embryonic development,integral to membrane,liver development,lung development,negative regulation of BMP signaling pathway,negative regulation of apoptotic process,negative regulation of calcium ion-dependent exocytosis,negative regulation of cell death,negative regulation of cell-substrate adhesion,negative regulation of glial cell proliferation,negative regulation of myoblast differentiation,negative regulation of oligodendrocyte differentiation,negative regulation of osteoblast differentiation,negative regulation of photoreceptor cell differentiation,negative regulation of pro-B cell differentiation,negative regulation of stem cell differentiation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,neural tube development,neuron fate commitment,neuronal stem cell maintenance,nucleoplasm,nucleus,organ regeneration,plasma membrane,positive regulation of BMP signaling pathway,positive regulation of JAK-STAT cascade,positive regulation of apoptotic process,positive regulation of astrocyte differentiation,positive regulation of cell proliferation,positive regulation of endothelial cell differentiation,positive regulation of epithelial cell proliferation,positive regulation of epithelial to mesenchymal transition,positive regulation of keratinocyte differentiation,positive regulation of neuroblast proliferation,positive regulation of transcription of Notch receptor target,positive regulation of transcription, DNA-dependent,prostate gland epithelium morphogenesis,protein binding,receptor activity,regulation of cardioblast proliferation,regulation of developmental process,regulation of epithelial cell proliferation involved in prostate gland development,regulation of neurogenesis,regulation of somitogenesis,regulation of transcription, DNA-dependent,response to corticosteroid stimulus,response to lipopolysaccharide,secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,somatic stem cell division,spermatogenesis,sprouting angiogenesis,tissue regeneration			0.00001	9245.23	G=1007, A=989		G=612/395, A=620/369	1	
chr9:139397707	G/A	G	SNV		NOTCH1	exonic	1								48.25	p.(=)		1716	G=0.5175, A=0.4825		Present				-	27	NM_017617.3	c.5094C>T	synonymous	-0.82				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,Laminin EGF-like (Domains III and V),NOTCH protein	rs10521		0.417 (ref)	0.3534	0.4829	0.408	YES	Golgi apparatus,Golgi lumen,MAML1-RBP-Jkappa- ICN1 complex,Notch receptor processing,Notch signaling pathway,acrosomal vesicle,anagen,aortic valve morphogenesis,axonogenesis,branching morphogenesis of a tube,calcium ion binding,cell differentiation in spinal cord,cell fate specification,chromatin DNA binding,compartment pattern specification,core promoter binding,cytoplasm,cytosol,determination of left/right symmetry,embryo development,embryonic hindlimb morphogenesis,endoderm development,endoplasmic reticulum lumen,extracellular region,forebrain development,foregut morphogenesis,gene expression,hair follicle morphogenesis,heart development,immune response,in utero embryonic development,integral to membrane,liver development,lung development,negative regulation of BMP signaling pathway,negative regulation of apoptotic process,negative regulation of calcium ion-dependent exocytosis,negative regulation of cell death,negative regulation of cell-substrate adhesion,negative regulation of glial cell proliferation,negative regulation of myoblast differentiation,negative regulation of oligodendrocyte differentiation,negative regulation of osteoblast differentiation,negative regulation of photoreceptor cell differentiation,negative regulation of pro-B cell differentiation,negative regulation of stem cell differentiation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,neural tube development,neuron fate commitment,neuronal stem cell maintenance,nucleoplasm,nucleus,organ regeneration,plasma membrane,positive regulation of BMP signaling pathway,positive regulation of JAK-STAT cascade,positive regulation of apoptotic process,positive regulation of astrocyte differentiation,positive regulation of cell proliferation,positive regulation of endothelial cell differentiation,positive regulation of epithelial cell proliferation,positive regulation of epithelial to mesenchymal transition,positive regulation of keratinocyte differentiation,positive regulation of neuroblast proliferation,positive regulation of transcription of Notch receptor target,positive regulation of transcription, DNA-dependent,prostate gland epithelium morphogenesis,protein binding,receptor activity,regulation of cardioblast proliferation,regulation of developmental process,regulation of epithelial cell proliferation involved in prostate gland development,regulation of neurogenesis,regulation of somitogenesis,regulation of transcription, DNA-dependent,response to corticosteroid stimulus,response to lipopolysaccharide,secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,somatic stem cell division,spermatogenesis,sprouting angiogenesis,tissue regeneration			0.00001	7614.94	G=888, A=828		G=460/428, A=475/353	1	
chr9:139407932	A/G	A	SNV		NOTCH1	exonic	1								50.05	p.(=)		1992	A=0.4995, G=0.5005		Present				-	14	NM_017617.3	c.2265T>C	synonymous	-1.25				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,Laminin EGF-like (Domains III and V),NOTCH protein	rs2229971		0.444 (ref)	0.2858	0.3844	0.3975	YES	Golgi apparatus,Golgi lumen,MAML1-RBP-Jkappa- ICN1 complex,Notch receptor processing,Notch signaling pathway,acrosomal vesicle,anagen,aortic valve morphogenesis,axonogenesis,branching morphogenesis of a tube,calcium ion binding,cell differentiation in spinal cord,cell fate specification,chromatin DNA binding,compartment pattern specification,core promoter binding,cytoplasm,cytosol,determination of left/right symmetry,embryo development,embryonic hindlimb morphogenesis,endoderm development,endoplasmic reticulum lumen,extracellular region,forebrain development,foregut morphogenesis,gene expression,hair follicle morphogenesis,heart development,immune response,in utero embryonic development,integral to membrane,liver development,lung development,negative regulation of BMP signaling pathway,negative regulation of apoptotic process,negative regulation of calcium ion-dependent exocytosis,negative regulation of cell death,negative regulation of cell-substrate adhesion,negative regulation of glial cell proliferation,negative regulation of myoblast differentiation,negative regulation of oligodendrocyte differentiation,negative regulation of osteoblast differentiation,negative regulation of photoreceptor cell differentiation,negative regulation of pro-B cell differentiation,negative regulation of stem cell differentiation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,neural tube development,neuron fate commitment,neuronal stem cell maintenance,nucleoplasm,nucleus,organ regeneration,plasma membrane,positive regulation of BMP signaling pathway,positive regulation of JAK-STAT cascade,positive regulation of apoptotic process,positive regulation of astrocyte differentiation,positive regulation of cell proliferation,positive regulation of endothelial cell differentiation,positive regulation of epithelial cell proliferation,positive regulation of epithelial to mesenchymal transition,positive regulation of keratinocyte differentiation,positive regulation of neuroblast proliferation,positive regulation of transcription of Notch receptor target,positive regulation of transcription, DNA-dependent,prostate gland epithelium morphogenesis,protein binding,receptor activity,regulation of cardioblast proliferation,regulation of developmental process,regulation of epithelial cell proliferation involved in prostate gland development,regulation of neurogenesis,regulation of somitogenesis,regulation of transcription, DNA-dependent,response to corticosteroid stimulus,response to lipopolysaccharide,secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,somatic stem cell division,spermatogenesis,sprouting angiogenesis,tissue regeneration			0.00001	9377.15	A=995, G=997		A=499/496, G=495/502	1	
chr9:139418260	A/G	A	SNV		NOTCH1	exonic	1								50.23	p.(=)		1314	A=0.4977, G=0.5023		Present				-	3	NM_017617.3	c.312T>C	synonymous	-1.16				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,Laminin EGF-like (Domains III and V),NOTCH protein	rs4489420		0.293 (ref)	0.4711	0.1191	0.3913	YES	Golgi apparatus,Golgi lumen,MAML1-RBP-Jkappa- ICN1 complex,Notch receptor processing,Notch signaling pathway,acrosomal vesicle,anagen,aortic valve morphogenesis,axonogenesis,branching morphogenesis of a tube,calcium ion binding,cell differentiation in spinal cord,cell fate specification,chromatin DNA binding,compartment pattern specification,core promoter binding,cytoplasm,cytosol,determination of left/right symmetry,embryo development,embryonic hindlimb morphogenesis,endoderm development,endoplasmic reticulum lumen,extracellular region,forebrain development,foregut morphogenesis,gene expression,hair follicle morphogenesis,heart development,immune response,in utero embryonic development,integral to membrane,liver development,lung development,negative regulation of BMP signaling pathway,negative regulation of apoptotic process,negative regulation of calcium ion-dependent exocytosis,negative regulation of cell death,negative regulation of cell-substrate adhesion,negative regulation of glial cell proliferation,negative regulation of myoblast differentiation,negative regulation of oligodendrocyte differentiation,negative regulation of osteoblast differentiation,negative regulation of photoreceptor cell differentiation,negative regulation of pro-B cell differentiation,negative regulation of stem cell differentiation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,neural tube development,neuron fate commitment,neuronal stem cell maintenance,nucleoplasm,nucleus,organ regeneration,plasma membrane,positive regulation of BMP signaling pathway,positive regulation of JAK-STAT cascade,positive regulation of apoptotic process,positive regulation of astrocyte differentiation,positive regulation of cell proliferation,positive regulation of endothelial cell differentiation,positive regulation of epithelial cell proliferation,positive regulation of epithelial to mesenchymal transition,positive regulation of keratinocyte differentiation,positive regulation of neuroblast proliferation,positive regulation of transcription of Notch receptor target,positive regulation of transcription, DNA-dependent,prostate gland epithelium morphogenesis,protein binding,receptor activity,regulation of cardioblast proliferation,regulation of developmental process,regulation of epithelial cell proliferation involved in prostate gland development,regulation of neurogenesis,regulation of somitogenesis,regulation of transcription, DNA-dependent,response to corticosteroid stimulus,response to lipopolysaccharide,secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,somatic stem cell division,spermatogenesis,sprouting angiogenesis,tissue regeneration			0.00001	6191.13	A=654, G=660		A=359/295, G=390/270	1	
chr10:43613843	G/T	G	SNV		RET	exonic	1								37.72	p.(=)		289	G=0.6228, T=0.3772		Present				+	13	NM_020975.4	c.2307G>T	synonymous	1.34				Cadherin domain,Protein kinase domain,Protein tyrosine kinase	rs1800861		0.277 (ref)	0.2347	0.1246	0.1974	YES	ATP binding,MAPKKK cascade,calcium ion binding,cellular response to retinoic acid,embryonic epithelial tube formation,endosome membrane,enteric nervous system development,homophilic cell adhesion,induction of apoptosis,integral to membrane,integral to plasma membrane,membrane,membrane protein proteolysis,nervous system development,neural crest cell migration,neuron maturation,nucleotide binding,positive regulation of cell adhesion mediated by integrin,positive regulation of cell migration,positive regulation of metanephric glomerulus development,positive regulation of neuron projection development,positive regulation of transcription, DNA-dependent,posterior midgut development,protein binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of cell adhesion,response to pain,signal transduction,transmembrane receptor protein tyrosine kinase activity,ureteric bud development	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo3,4-DPyrimidin-4-Ylamine,4-BROMO-2-FLUORO-N-(4E)-6-METHOXY-7-(1-METHYLPIPERIDIN-4-YL)METHOXYQUINAZOLIN-4(1H)-YLIDENEANILINE,Imatinib	untested	0.00001	785.737	G=180, T=109		G=88/92, T=47/62	1	
chr10:43615633	C/G	C	SNV		RET	exonic	1								51.44	p.(=)		381	C=0.4856, G=0.5144		Present				+	15	NM_020975.4	c.2712C>G	synonymous	0.73				Cadherin domain,Protein kinase domain,Protein tyrosine kinase	rs1800863		0.16 (ref)	0.1866	0.111	0.1609	YES	ATP binding,MAPKKK cascade,calcium ion binding,cellular response to retinoic acid,embryonic epithelial tube formation,endosome membrane,enteric nervous system development,homophilic cell adhesion,induction of apoptosis,integral to membrane,integral to plasma membrane,membrane,membrane protein proteolysis,nervous system development,neural crest cell migration,neuron maturation,nucleotide binding,positive regulation of cell adhesion mediated by integrin,positive regulation of cell migration,positive regulation of metanephric glomerulus development,positive regulation of neuron projection development,positive regulation of transcription, DNA-dependent,posterior midgut development,protein binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of cell adhesion,response to pain,signal transduction,transmembrane receptor protein tyrosine kinase activity,ureteric bud development	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo3,4-DPyrimidin-4-Ylamine,4-BROMO-2-FLUORO-N-(4E)-6-METHOXY-7-(1-METHYLPIPERIDIN-4-YL)METHOXYQUINAZOLIN-4(1H)-YLIDENEANILINE,Imatinib	non-pathogenic	0.00001	1860.99	C=185, G=196		C=84/101, G=97/99	2	
chr10:123298158	C/C	T	SNV		FGFR2	exonic	1								98.56	p.(=)		277	T=0.0144, C=0.9856		Present				-	6	NM_000141.4	c.696A>G	synonymous	0.96				Immunoglobulin I-set domain,Immunoglobulin V-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs1047100		0.176 (ref)	0.2236	0.2522	0.2333	YES	ATP binding,Golgi apparatus,angiogenesis,apoptotic process,axonogenesis,bone development,bone mineralization,bone morphogenesis,branch elongation involved in salivary gland morphogenesis,branching involved in embryonic placenta morphogenesis,branching involved in prostate gland morphogenesis,branching involved in salivary gland morphogenesis,branching morphogenesis of a nerve,bud elongation involved in lung branching,cell cortex,cell fate commitment,cell surface,cell-cell signaling,cytoplasm,cytoplasmic membrane-bounded vesicle,digestive tract development,embryonic digestive tract morphogenesis,embryonic organ development,embryonic organ morphogenesis,embryonic pattern specification,epidermis morphogenesis,epithelial cell differentiation,epithelial cell proliferation involved in salivary gland morphogenesis,excitatory synapse,extracellular matrix,extracellular region,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor receptor signaling pathway involved in hemopoiesis,fibroblast growth factor receptor signaling pathway involved in mammary gland specification,fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow,fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development,fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow,fibroblast growth factor-activated receptor activity,gland morphogenesis,hair follicle morphogenesis,heparin binding,in utero embryonic development,inner ear morphogenesis,insulin receptor signaling pathway,integral to membrane,integral to plasma membrane,lacrimal gland development,lateral sprouting from an epithelium,limb bud formation,lung alveolus development,lung development,lung lobe morphogenesis,lung-associated mesenchyme development,mammary gland bud formation,membrane,membranous septum morphogenesis,mesenchymal cell differentiation,mesenchymal cell differentiation involved in lung development,mesenchymal cell proliferation involved in lung development,midbrain development,morphogenesis of embryonic epithelium,multicellular organism growth,negative regulation of transcription from RNA polymerase II promoter,nucleotide binding,nucleus,odontogenesis,orbitofrontal cortex development,organ growth,organ morphogenesis,otic vesicle formation,outflow tract septum morphogenesis,peptidyl-tyrosine phosphorylation,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of MAPKKK cascade,positive regulation of Wnt receptor signaling pathway,positive regulation of canonical Wnt receptor signaling pathway,positive regulation of cardiac muscle cell proliferation,positive regulation of cell cycle,positive regulation of cell division,positive regulation of cell proliferation,positive regulation of epithelial cell proliferation,positive regulation of epithelial cell proliferation involved in lung morphogenesis,positive regulation of mesenchymal cell proliferation,positive regulation of phospholipase activity,positive regulation of transcription from RNA polymerase II promoter,post-embryonic development,prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis,prostate epithelial cord elongation,prostate gland morphogenesis,protein autophosphorylation,protein binding,protein homodimerization activity,protein tyrosine kinase activity,pyramidal neuron development,receptor activity,regulation of ERK1 and ERK2 cascade,regulation of branching involved in prostate gland morphogenesis,regulation of cell fate commitment,regulation of fibroblast growth factor receptor signaling pathway,regulation of morphogenesis of a branching structure,regulation of multicellular organism growth,regulation of osteoblast differentiation,regulation of osteoblast proliferation,regulation of smooth muscle cell differentiation,regulation of smoothened signaling pathway,reproductive structure development,skeletal system morphogenesis,squamous basal epithelial stem cell differentiation involved in prostate gland acinus development,ureteric bud development,ventricular cardiac muscle tissue morphogenesis,ventricular zone neuroblast division	4-4-(1-Amino-1-Methylethyl)Phenyl-5-Chloro-N-4-(2-Morpholin-4-Ylethyl)PhenylPyrimidin-2-Amine,Palifermin,SU4984,Thalidomide		0.00001	4076.99	T=4, C=273		T=4/0, C=133/140	1	
chr11:534242	G/G	A	SNV		HRAS	exonic	1								100.00	p.(=)		1682	A=0.0, G=1.0		Present				-	2	NM_001130442.1	c.81T>C	synonymous	-0.0				Miro-like protein,Ras family	rs12628		0.297 (ref)	0.3441	0.3749	0.3545	YES	GTP binding,GTPase activity,Golgi apparatus,Golgi membrane,MAPKKK cascade,Ral guanyl-nucleotide exchange factor activity,Ras protein signal transduction,actin cytoskeleton organization,activation of MAPKK activity,apoptotic process,axon guidance,blood coagulation,cell cycle arrest,cell surface receptor linked signaling pathway,cellular senescence,chemotaxis,cytoplasm,cytosol,endocytosis,epidermal growth factor receptor signaling pathway,induction of apoptosis by intracellular signals,insulin receptor signaling pathway,leukocyte migration,membrane fraction,microsome,mitotic cell cycle G1/S transition checkpoint,negative regulation of cell proliferation,negative regulation of neuron apoptosis,nerve growth factor receptor signaling pathway,nucleotide binding,nucleus,organ morphogenesis,perinuclear region of cytoplasm,plasma membrane,positive regulation of DNA replication,positive regulation of ERK1 and ERK2 cascade,positive regulation of MAPKKK cascade,positive regulation of Rac protein signal transduction,positive regulation of cell proliferation,positive regulation of epithelial cell proliferation,protein C-terminus binding,protein binding,regulation of long-term neuronal synaptic plasticity,regulation of synaptic transmission, GABAergic,signal transduction,small GTPase mediated signal transduction,social behavior,soluble fraction,striated muscle cell differentiation,synaptic transmission,visual learning	Guanosine-5'-Diphosphate,Guanosine-5'-Triphosphate,Hexane-1,6-Diol,N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE,Trifluoroethanol		0.00001	25351.3	A=0, G=1682		A=0/0, G=849/833	4	
chr11:108121636	A/C	A	SNV		ATM	exonic	1								44.52	p.Lys482Gln		146	A=0.5548, C=0.4452		Present				+	10	NM_000051.3	c.1444A>C	missense	2.2	0.01	53.0	0.651	FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase	rs202173660		0.0 (ref)	1.0E-4	0.0	1.0E-4		1-phosphatidylinositol-3-kinase activity,ATP binding,DNA binding,DNA damage induced protein phosphorylation,DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,DNA damage response, signal transduction resulting in induction of apoptosis,DNA repair,DNA-dependent protein kinase activity,G2/M transition DNA damage checkpoint,brain development,cell cycle arrest,cell cycle checkpoint,cell death,cellular response to gamma radiation,chromosome, telomeric region,cytoplasm,cytoplasmic membrane-bounded vesicle,double-strand break repair,double-strand break repair via homologous recombination,female gamete generation,heart development,histone mRNA catabolic process,histone serine kinase activity,lipoprotein catabolic process,mitotic cell cycle spindle assembly checkpoint,negative regulation of B cell proliferation,negative regulation of apoptotic process,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,positive regulation of apoptotic process,positive regulation of neuron apoptosis,pre-B cell allelic exclusion,protein N-terminus binding,protein autophosphorylation,protein binding,protein complex binding,protein dimerization activity,protein serine/threonine kinase activity,reciprocal meiotic recombination,regulation of cell cycle,replicative senescence,response to DNA damage stimulus,response to hypoxia,response to ionizing radiation,signal transduction,somitogenesis,spindle			0.00001	571.358	A=81, C=65		A=36/45, C=31/34	4	
chr11:108175462	G/A	G	SNV		ATM	exonic	1	Hotspot	Loss-of-function						49.01	p.Asp1853Asn		1673	G=0.5099, A=0.4901		Present				+	37	NM_000051.3	c.5557G>A	missense	2.75	0.07	23.0	0.044	FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase	rs1801516		0.079 (ref)	0.1402	0.0284	0.1023	YES	1-phosphatidylinositol-3-kinase activity,ATP binding,DNA binding,DNA damage induced protein phosphorylation,DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,DNA damage response, signal transduction resulting in induction of apoptosis,DNA repair,DNA-dependent protein kinase activity,G2/M transition DNA damage checkpoint,brain development,cell cycle arrest,cell cycle checkpoint,cell death,cellular response to gamma radiation,chromosome, telomeric region,cytoplasm,cytoplasmic membrane-bounded vesicle,double-strand break repair,double-strand break repair via homologous recombination,female gamete generation,heart development,histone mRNA catabolic process,histone serine kinase activity,lipoprotein catabolic process,mitotic cell cycle spindle assembly checkpoint,negative regulation of B cell proliferation,negative regulation of apoptotic process,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,positive regulation of apoptotic process,positive regulation of neuron apoptosis,pre-B cell allelic exclusion,protein N-terminus binding,protein autophosphorylation,protein binding,protein complex binding,protein dimerization activity,protein serine/threonine kinase activity,reciprocal meiotic recombination,regulation of cell cycle,replicative senescence,response to DNA damage stimulus,response to hypoxia,response to ionizing radiation,signal transduction,somitogenesis,spindle			0.00001	7527.82	G=853, A=820		G=423/430, A=403/417	1	
chr11:108183167	G/G	A	SNV		ATM	exonic	1								98.07	p.Asn1983Ser		1298	A=0.0193, G=0.9807		Present				+	40	NM_000051.3	c.5948A>G	missense	-0.19	1.0	46.0	0.0	FAT domain,FATC domain,Phosphatidylinositol 3- and 4-kinase	rs659243		0.0 (ref)					1-phosphatidylinositol-3-kinase activity,ATP binding,DNA binding,DNA damage induced protein phosphorylation,DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,DNA damage response, signal transduction resulting in induction of apoptosis,DNA repair,DNA-dependent protein kinase activity,G2/M transition DNA damage checkpoint,brain development,cell cycle arrest,cell cycle checkpoint,cell death,cellular response to gamma radiation,chromosome, telomeric region,cytoplasm,cytoplasmic membrane-bounded vesicle,double-strand break repair,double-strand break repair via homologous recombination,female gamete generation,heart development,histone mRNA catabolic process,histone serine kinase activity,lipoprotein catabolic process,mitotic cell cycle spindle assembly checkpoint,negative regulation of B cell proliferation,negative regulation of apoptotic process,nucleoplasm,nucleotide binding,nucleus,peptidyl-serine phosphorylation,positive regulation of DNA damage response, signal transduction by p53 class mediator,positive regulation of apoptotic process,positive regulation of neuron apoptosis,pre-B cell allelic exclusion,protein N-terminus binding,protein autophosphorylation,protein binding,protein complex binding,protein dimerization activity,protein serine/threonine kinase activity,reciprocal meiotic recombination,regulation of cell cycle,replicative senescence,response to DNA damage stimulus,response to hypoxia,response to ionizing radiation,signal transduction,somitogenesis,spindle			0.00001	18847.3	A=25, G=1273		A=15/10, G=682/591	2	
chr11:125525195	G/G	A	SNV		CHEK1	exonic	1								100.00	p.Ile471Val		1576	A=0.0, G=1.0		Present				+	13	NM_001274.5	c.1411A>G	missense	0.45	1.0	29.0	0.0	Protein kinase domain,Protein tyrosine kinase	rs506504		0.017 (ref)	0.0363	0.0064	0.0262	YES	ATP binding,DNA damage checkpoint,DNA damage induced protein phosphorylation,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,G2/M transition of mitotic cell cycle,cell cycle,cell cycle checkpoint,cellular response to caffeine,cellular response to mechanical stimulus,cellular response to organic substance,centrosome,chromatin,chromatin-mediated maintenance of transcription,chromosome, telomeric region,condensed nuclear chromosome,cytoplasm,cytoskeleton,histone H3-T11 phosphorylation,histone kinase activity (H3-T11 specific),negative regulation of mitosis,nucleoplasm,nucleotide binding,nucleus,peptidyl-threonine phosphorylation,protein binding,protein serine/threonine kinase activity,regulation of S phase,regulation of double-strand break repair via homologous recombination,regulation of histone H3-K9 acetylation,regulation of mitotic centrosome separation,regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage,replication fork,replicative senescence,response to DNA damage stimulus	(2R)-1-(5,6-DIPHENYL-7H-PYRROLO2,3-DPYRIMIDIN-4-YL)AMINOPROPAN-2-OL,(2R)-3-{(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO2,3-DPYRIMIDIN-4-YLIDENEAMINO}PROPANE-1,2-DIOL,(2S)-1-AMINO-3-(5-NITROQUINOLIN-8-YL)AMINOPROPAN-2-OL,(3-ENDO)-8-METHYL-8-AZABICYCLO3.2.1OCT-3-YL 1H-PYRROLO2,3-BPYRIDINE-3-CARBOXYLATE,(3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE,(5,6-DIPHENYL-FURO2,3-DPYRIMIDIN-4-YLAMINO)-ACETIC,(5-{3-5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL,1-(2S)-4-(5-BROMO-1H-PYRAZOLO3,4-BPYRIDIN-4-YL)MORPHOLIN-2-YLMETHANAMINE,1-(2S)-4-(5-phenyl-1H-pyrazolo3,4-bpyridin-4-yl)morpholin-2-ylmethanamine,1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA,1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-2-(DIMETHYLAMINO)-1-METHYLETHOXYPYRAZIN-2-YL}UREA,18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE,2,2'-{9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYLBIS(OXY)}DIACETIC ACID,2-(5,6-DIPHENYLFURO2,3-DPYRIMIDIN-4-YL)AMINOETHANOL,2-(cyclohexylamino)benzoic acid,2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol,2-5,6-BIS-(4-METHOXY-PHENYL)-FURO2,3-DPYRIMIDIN-4-YLAMINO-ETHANOL,3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE,3-(5-{4-(AMINOMETHYL)PIPERIDIN-1-YLMETHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE,3-(5-{4-(AMINOMETHYL)PIPERIDIN-1-YLMETHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE,3-AMINO-3-BENZYL-4.3.0BICYCLO-1,6-DIAZANONAN-2-ONE,4-(3S)-1-AZABICYCLO2.2.2OCT-3-YLAMINO-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE,4-(6-{(4-METHYLCYCLOHEXYL)AMINOMETHYL}-1,4-DIHYDROINDENO1,2-CPYRAZOL-3-YL)BENZOIC ACID,4-3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL-2-METHOXYPHENOL,4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl(phenyl)methanone,5,6,7,8-TETRAHYDRO1BENZOTHIENO2,3-DPYRIMIDIN-4(3H)-ONE,5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO4,3-CQUINOLIN-4-ONE,6-MORPHOLIN-4-YL-9H-PURINE,N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-1,3THIAZOLO5,4-CAZEPIN-2-YL)ACETAMIDE,N-(5,6-DIPHENYLFURO2,3-DPYRIMIDIN-4-YL)GLYCINE,N-{5-4-(4-METHYLPIPERAZIN-1-YL)PHENYL-1H-PYRROLO2,3-BPYRIDIN-3-YL}NICOTINAMIDE,REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO1,2,3-FG:3',2',1'-KLPYRROLO3,4-I1,6BENZODIAZOCINE-1,3(2H)-DIONE		0.00001	23762.8	A=0, G=1576		A=0/0, G=730/846	1	
chr12:25368462	T/T	C	SNV		KRAS	exonic	1								100.00	p.(=)		523	C=0.0, T=1.0		Present				-	5	NM_033360.3	c.483G>A	synonymous	1.06				Miro-like protein,Ras family	rs4362222		0.0 (ref)	0.0	0.0043	0.0015		GDP binding,GMP binding,GTP binding,GTPase activity,LRR domain binding,MAPKKK cascade,Ral guanyl-nucleotide exchange factor activity,Ras protein signal transduction,activation of MAPKK activity,axon guidance,blood coagulation,cytokine-mediated signaling pathway,epidermal growth factor receptor signaling pathway,insulin receptor signaling pathway,leukocyte migration,membrane raft,mitochondrion,nerve growth factor receptor signaling pathway,nucleotide binding,plasma membrane,positive regulation of MAP kinase activity,positive regulation of NF-kappaB transcription factor activity,positive regulation of nitric-oxide synthase activity,protein binding,response to glucocorticoid stimulus,response to mineralocorticoid stimulus,signal transduction,small GTPase mediated signal transduction,social behavior	(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL-PHOSPHONIC ACID,FARNESYL,FARNESYL DIPHOSPHATE		0.00001	7810.16	C=0, T=523		C=0/0, T=276/247	3	
chr12:56360876	G/A	G	SNV		CDK2	exonic	1								42.73	p.(=)		447	G=0.5727, A=0.4273		Present				+	1	NM_001798.3	c.84G>A	synonymous	0.08				Protein kinase domain,Protein tyrosine kinase	rs2069398		0.101 (ref)	0.0773	0.2783	0.1454	YES	ATP binding,Cajal body,DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,DNA repair,DNA replication,G1/S transition of mitotic cell cycle,G2 phase of mitotic cell cycle,G2/M transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,Ras protein signal transduction,S phase of mitotic cell cycle,X chromosome,Y chromosome,anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process,blood coagulation,cell cycle,cell cycle checkpoint,cell division,cellular response to nitric oxide,centrosome,centrosome duplication,chromosome, telomeric region,condensed chromosome,cyclin binding,cyclin-dependent protein kinase activity,cyclin-dependent protein kinase holoenzyme complex,cytoplasm,cytoskeleton,cytosol,endosome,histone kinase activity,histone phosphorylation,kinase activity,meiosis,metal ion binding,mitosis,mitotic cell cycle,mitotic cell cycle G1/S transition DNA damage checkpoint,nucleoplasm,nucleotide binding,nucleus,phosphorylation,positive regulation of cell proliferation,positive regulation of transcription, DNA-dependent,potassium ion transport,protein binding,protein kinase activity,protein phosphorylation,regulation of DNA replication,regulation of gene silencing,regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle,transcription factor complex,traversing start control point of mitotic cell cycle	(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO15.6.2.16,9.1,12,15.0,2,7.0,21,25HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE,(2R)-1-(DIMETHYLAMINO)-3-{4-(6-{2-FLUORO-5-(TRIFLUOROMETHYL)PHENYLAMINO}PYRIMIDIN-4-YL)AMINOPHENOXY}PROPAN-2-OL,(2R)-1-4-({4-(2,5-DICHLOROPHENYL)AMINOPYRIMIDIN-2-YL}AMINO)PHENOXY-3-(DIMETHYLAMINO)PROPAN-2-OL,(2R)-1-4-({6-(2,6-DIFLUOROPHENYL)AMINOPYRIMIDIN-4-YL}AMINO)PHENOXY-3-(DIMETHYLAMINO)PROPAN-2-OL,(2R)-1-{4-(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINOPHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL,(2R)-2-({9-(1-methylethyl)-6-(4-pyridin-2-ylbenzyl)amino-9H-purin-2-yl}amino)butan-1-ol,(2R)-2-{4-(benzylamino)-8-(1-methylethyl)pyrazolo1,5-a1,3,5triazin-2-ylamino}butan-1-ol,(2S)-1-4-({4-(2,5-DICHLOROPHENYL)AMINOPYRIMIDIN-2-YL}AMINO)PHENOXY-3-(DIMETHYLAMINO)PROPAN-2-OL,(2S)-1-4-({6-(2,6-DIFLUOROPHENYL)AMINOPYRIMIDIN-4-YL}AMINO)PHENOXY-3-(DIMETHYLAMINO)PROPAN-2-OL,(2S)-1-{4-(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINOPHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL,(2S)-N-(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE-2-4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYLPROPANAMIDE,(2Z)-5'-BROMO-2,3'-BIINDOLE-2',3(1H,1'H)-DIONE AMMONIATE,(2e,3s)-3-Hydroxy-5'-(4-Hydroxypiperidin-1-Yl)Sulfonyl-3-Methyl-1,3-Dihydro-2,3'-Biindol-2'(1'h)-One,(3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-1benzothieno3,2-e1,4diazepin-5-one,(4-AMINO-2-{1-(METHYLSULFONYL)PIPERIDIN-4-YLAMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE,(4E)-N-(4-fluorophenyl)-4-(phenylcarbonyl)imino-4H-pyrazole-3-carboxamide,(5-Chloropyrazolo1,5-aPyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine,(5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo1,5-apyrimidin-3-yl)methanol,(5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO1,5-APYRIMIDIN-7-AMINE,1-(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy-3-Methyl-2-Butanol,1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID,1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO1,2-CPYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA,1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO2,1-AISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA,1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO1,2-APYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO}PHENOXY)PROPAN-2-OL,1-4-(AMINOSULFONYL)PHENYL-1,6-DIHYDROPYRAZOLO3,4-EINDAZOLE-3-CARBOXAMIDE,1-Amino-6-Cyclohex-3-Enylmethyloxypurine,1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo4,3-hquinazoline-3-carboxylic acid,2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE,2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO1,2-CPYRAZOL-5-YL)ACETAMIDE,2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE,2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo1,2-aPyridin-3-Yl-Phenyl-Methanone,2-Amino-6-Chloropyrazine,2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE,2-Trans-(4-Aminocyclohexyl)Amino-6-(Benzyl-Amino)-9-Cyclopentylpurine,2-{4-4-({4-2-methyl-1-(1-methylethyl)-1H-imidazol-5-ylpyrimidin-2-yl}amino)phenylpiperazin-1-yl}-2-oxoethanol,3-((3-bromo-5-o-tolylpyrazolo1,5-apyrimidin-7-ylamino)methyl)pyridine 1-oxide,3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE,3-({2-(4-{6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YLAMINO}PHENYL)SULFONYLETHYL}AMINO)PROPAN-1-OL,3-4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino-Phenol,3-Pyridin-4-Yl-2,4-Dihydro-Indeno1,2-.C.Pyrazole,3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo1,5-apyrimidin-7-amine,3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo1,5-apyrimidin-7-amine,3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo1,5-apyridin-7-amine,3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo1,2-apyridin-8-amine,3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo1,5-apyrimidin-7-amine,3-methyl-N-(pyridin-4-ylmethyl)imidazo1,2-apyrazin-8-amine,3-{(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINOMETHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE,3-{4-(AMINO(IMINO)METHYLAMINOSULFONYL)ANILINOMETHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE,4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene-1,3-Dihydro-Indol-2-One,4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl-(4-Trifluoromethyl-Phenyl)-Amine,4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine,4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine,4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl-(3-Nitro-Phenyl)-Amine,4-(4-Imidazo1,2-aPyridin-3-Ylpyrimidin-2-Yl)AminoBenzenesulfonamide,4-(4-methoxy-1H-pyrrolo2,3-bpyridin-3-yl)pyrimidin-2-amine,4-(4-propoxy-1H-pyrrolo2,3-bpyridin-3-yl)pyrimidin-2-amine,4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide,4-(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINOBENZENESULFONAMIDE,4-(6-Amino-4-Pyrimidinyl)AminoBenzenesulfonamide,4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE,4-(6-chloropyrazin-2-yl)aminobenzenesulfonamide,4-(7-OXO-7H-THIAZOLO5,4-EINDOL-8-YLMETHYL)-AMINO-N-PYRIDIN-2-YL-BENZENESULFONAMIDE,4-(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYLPHENOL,4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide,4-({5-(4-AMINOCYCLOHEXYL)AMINO1,2,4TRIAZOLO1,5-APYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE,4-3-Hydroxyanilino-6,7-Dimethoxyquinazoline,4-4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino-Phenol,4-5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo1,5-aPyrimidin-7-Ylamino-N,N-Dimethylbenzenesulfonamide,4-METHYL-5-{(2E)-2-(4-MORPHOLIN-4-YLPHENYL)IMINO-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE,4-{(2,6-dichlorophenyl)carbonylamino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide,4-{(2,6-difluorophenyl)carbonylamino}-N-(3S)-piperidin-3-yl-1H-pyrazole-3-carboxamide,4-{(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYLAMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE,4-{4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YLAMINO}-N-METHYLBENZENESULFONAMIDE,4-{4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YLAMINO}BENZAMIDE,4-{5-(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL-2-FURYL}BENZENESULFONAMIDE,4-{5-(CYCLOHEXYLAMINO)1,2,4TRIAZOLO1,5-APYRIMIDIN-7-YLAMINO}BENZENESULFONAMIDE,4-{5-(CYCLOHEXYLMETHOXY)1,2,4TRIAZOLO1,5-APYRIMIDIN-7-YLAMINO}BENZENESULFONAMIDE,4-{5-(CYCLOHEXYLOXY)1,2,4TRIAZOLO1,5-APYRIMIDIN-7-YLAMINO}BENZENESULFONAMIDE,4-{5-(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYLFURAN-2-YL}BENZENESULFONAMIDE,4-{5-(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL-2-FURYL}-N-METHYLBENZENESULFONAMIDE,4-{5-(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYLFURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE,4-{5-(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYLFURAN-2-YL}BENZENESULFONAMIDE,4-{5-(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYLFURAN-2-YL}BENZOIC ACID,5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo1,5-apyrimidin-7-amine,5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo1,5-apyrimidin-7-amine,5-(2-AMINOETHYL)AMINO-6-FLUORO-3-(1H-PYRROL-2-YL)BENZOCDINDOL-2(1H)-ONE,5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo1,5-apyrimidin-7-amine,5-(4-AMINOCYCLOHEXYL)AMINO-7-(PROPAN-2-YLAMINO)PYRAZOLO1,5-APYRIMIDINE-3-CARBONITRILE,5-5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL-3-{1-(2-CHLOROPHENYL)ETHYLOXY}-2-THIOPHENECARBOXAMIDE,5-chloro-7-(1-methylethyl)aminopyrazolo1,5-apyrimidine-3-carbonitrile,5-hydroxynaphthalene-1-sulfonamide,5-{(2-Amino-9h-Purin-6-Yl)OxyMethyl}-2-Pyrrolidinone,6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo1,2-apyrazin-8-amine,6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO3,4-DPYRIMIDIN-4(5H)-ONE,6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE,6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE,6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO12.3.1.1~3,7~NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE,6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE,6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE,6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE,6-O-Cyclohexylmethyl Guanine,9-amino-5-(2-aminopyrimidin-4-yl)pyrido3',2':4,5pyrrolo1,2-cpyrimidin-4-ol,Double Oxidized Cysteine,Flavopiridol,HYDROXY(OXO)(3-{(2Z)-4-3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYLPYRIMIDIN-2(5H)-YLIDENEAMINO}PHENYL)AMMONIUM,Hymenialdisine,Indirubin-3'-Monoxime,Lysine Nz-Carboxylic Acid,N'-(Pyrrolidino2,1-BIsoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea,N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo1,5-apyrimidin-7-amine,N-(2-METHOXYETHYL)-4-({4-2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YLPYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE,N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL)ACETAMIDE,N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE,N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide,N-(4-{(3S)-3-(dimethylamino)pyrrolidin-1-ylcarbonyl}phenyl)-5-fluoro-4-2-methyl-1-(1-methylethyl)-1H-imidazol-5-ylpyrimidin-2-amine,N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide,N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE,N-3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YLBENZAMIDE,N-4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE,N-4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl-N'-Hydroxyimidoformamide,N-4-(2-Methylimidazo1,2-aPyridin-3-Yl)-2-PyrimidinylAcetamide,N-5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE,N-METHYL-4-{(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYLAMINO}BENZENESULFONAMIDE,N-METHYL-{4-2-(7-OXO-6,7-DIHYDRO-8H-1,3THIAZOLO5,4-EINDOL-8-YLIDENE)HYDRAZINOPHENYL}METHANESULFONAMIDE,N-cyclopropyl-4-pyrazolo1,5-bpyridazin-3-ylpyrimidin-2-amine,N-phenyl-1H-pyrazole-3-carboxamide,O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE,OLOMOUCINE II,Olomoucine,PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE,Purvalanol,SU9516,Staurosporine,TRIAZOLOPYRIMIDINE,{(2,6-difluorophenyl)carbonylamino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide		0.00001	1609.19	G=256, A=191		G=136/120, A=111/80	2	
chr12:133208979	T/C	T	SNV		POLE	exonic	1								47.28	p.(=)		404	T=0.5272, C=0.4728		Present				-	45	NM_006231.3	c.6252A>G	synonymous	-2.14				DNA polymerase family B,Domain of unknown function (DUF1744)	rs5745022		0.307 (ref)	0.4157	0.2433	0.3573	YES	DNA binding,DNA repair,DNA replication,DNA synthesis involved in DNA repair,DNA-dependent DNA replication initiation,DNA-directed DNA polymerase activity,G1/S transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,S phase of mitotic cell cycle,base-excision repair, gap-filling,chromatin binding,in utero embryonic development,metal ion binding,mitotic cell cycle,nucleobase-containing compound metabolic process,nucleoplasm,nucleotide binding,nucleotide-excision repair,nucleotide-excision repair, DNA gap filling,nucleotidyltransferase activity,nucleus,telomere maintenance,telomere maintenance via recombination,telomere maintenance via semi-conservative replication,transcription-coupled nucleotide-excision repair,transferase activity,zinc ion binding	Cladribine		0.00001	1710.49	T=213, C=191		T=95/118, C=97/94	1	
chr12:133212582	G/A	G	SNV		POLE	exonic	1								47.19	p.(=)		231	G=0.5281, A=0.4719		Present				-	42	NM_006231.3	c.5707C>T	synonymous	-0.23				DNA polymerase family B,Domain of unknown function (DUF1744)	rs5744990		0.135 (ref)	0.1601	0.1455	0.1552	YES	DNA binding,DNA repair,DNA replication,DNA synthesis involved in DNA repair,DNA-dependent DNA replication initiation,DNA-directed DNA polymerase activity,G1/S transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,S phase of mitotic cell cycle,base-excision repair, gap-filling,chromatin binding,in utero embryonic development,metal ion binding,mitotic cell cycle,nucleobase-containing compound metabolic process,nucleoplasm,nucleotide binding,nucleotide-excision repair,nucleotide-excision repair, DNA gap filling,nucleotidyltransferase activity,nucleus,telomere maintenance,telomere maintenance via recombination,telomere maintenance via semi-conservative replication,transcription-coupled nucleotide-excision repair,transferase activity,zinc ion binding	Cladribine		0.00001	986.392	G=122, A=109		G=60/62, A=47/62	1	
chr12:133240698	G/A	G	SNV		POLE	exonic	1								24.76	p.(=)		1999	G=0.7524, A=0.2476		Present				-	23	NM_006231.3	c.2598C>T	synonymous	-1.45				DNA polymerase family B,Domain of unknown function (DUF1744)								DNA binding,DNA repair,DNA replication,DNA synthesis involved in DNA repair,DNA-dependent DNA replication initiation,DNA-directed DNA polymerase activity,G1/S transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,S phase of mitotic cell cycle,base-excision repair, gap-filling,chromatin binding,in utero embryonic development,metal ion binding,mitotic cell cycle,nucleobase-containing compound metabolic process,nucleoplasm,nucleotide binding,nucleotide-excision repair,nucleotide-excision repair, DNA gap filling,nucleotidyltransferase activity,nucleus,telomere maintenance,telomere maintenance via recombination,telomere maintenance via semi-conservative replication,transcription-coupled nucleotide-excision repair,transferase activity,zinc ion binding	Cladribine		0.00001	2915.82	G=1504, A=495		G=661/843, A=211/284	1	
chr12:133242016	C/T	C	SNV		POLE	exonic	1								38.79	p.(=)		776	C=0.6121, T=0.3879		Present				-	21	NM_006231.3	c.2340G>A	synonymous	-4.04				DNA polymerase family B,Domain of unknown function (DUF1744)	rs5744822		0.025 (ref)	0.023	0.0039	0.0165	YES	DNA binding,DNA repair,DNA replication,DNA synthesis involved in DNA repair,DNA-dependent DNA replication initiation,DNA-directed DNA polymerase activity,G1/S transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,S phase of mitotic cell cycle,base-excision repair, gap-filling,chromatin binding,in utero embryonic development,metal ion binding,mitotic cell cycle,nucleobase-containing compound metabolic process,nucleoplasm,nucleotide binding,nucleotide-excision repair,nucleotide-excision repair, DNA gap filling,nucleotidyltransferase activity,nucleus,telomere maintenance,telomere maintenance via recombination,telomere maintenance via semi-conservative replication,transcription-coupled nucleotide-excision repair,transferase activity,zinc ion binding	Cladribine		0.00001	2402.84	C=475, T=301		C=171/304, T=131/170	2	
chr12:133253995	G/A	G	SNV		POLE	exonic	1								44.80	p.Ala252Val		500	G=0.552, A=0.448		Present				-	8	NM_006231.3	c.755C>T	missense	2.65	0.64	64.0	0.007	DNA polymerase family B,Domain of unknown function (DUF1744)	rs5744751		0.072 (ref)	0.1073	0.0159	0.0763	YES	DNA binding,DNA repair,DNA replication,DNA synthesis involved in DNA repair,DNA-dependent DNA replication initiation,DNA-directed DNA polymerase activity,G1/S transition of mitotic cell cycle,M/G1 transition of mitotic cell cycle,S phase of mitotic cell cycle,base-excision repair, gap-filling,chromatin binding,in utero embryonic development,metal ion binding,mitotic cell cycle,nucleobase-containing compound metabolic process,nucleoplasm,nucleotide binding,nucleotide-excision repair,nucleotide-excision repair, DNA gap filling,nucleotidyltransferase activity,nucleus,telomere maintenance,telomere maintenance via recombination,telomere maintenance via semi-conservative replication,transcription-coupled nucleotide-excision repair,transferase activity,zinc ion binding	Cladribine		0.00001	1929.46	G=276, A=224		G=112/164, A=106/118	1	
chr13:28636084	A/A	G	SNV		FLT3	exonic	1								100.00	p.(=)		1229	G=0.0, A=1.0		Present				-	3	NM_004119.2	c.288C>T	synonymous	0.04				Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs7338903		0.041 (ref)	0.0105	0.0978	0.0401	YES	ATP binding,cell surface,cellular response to cytokine stimulus,cytokine receptor activity,cytokine-mediated signaling pathway,endoplasmic reticulum,endoplasmic reticulum lumen,hemopoiesis,integral to plasma membrane,lymphocyte differentiation,membrane,myeloid progenitor cell differentiation,negative regulation of B cell differentiation,negative regulation of cell proliferation,nucleotide binding,peptidyl-tyrosine phosphorylation,phosphatidylinositol 3-kinase binding,positive regulation of MAP kinase activity,positive regulation of MAPKKK cascade,positive regulation of cell proliferation,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of tyrosine phosphorylation of STAT protein,pro-B cell differentiation,pro-T cell differentiation,protein autophosphorylation,protein homodimerization activity,receptor activity,regulation of apoptotic process,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway,vascular endothelial growth factor receptor signaling pathway,vascular endothelial growth factor-activated receptor activity	Sorafenib,Sunitinib		0.00001	18715.3	G=0, A=1229		G=0/0, A=625/604	1	
chr13:32899321		G	GENE_EXPRESSION		BRCA2								BRCA2.E5E6				251				NoCall			7.8266e-08																						0.0					
chr13:32900750		G	GENE_EXPRESSION		BRCA2								BRCA2-BRCA2.B7B10.V8				592				NoCall			1.8460e-07																						0.0					
chr13:32906729	A/C	A	SNV		BRCA2	exonic	1								47.01	p.Asn372His		1306	A=0.5299, C=0.4701		Present				+	10	NM_000059.3	c.1114A>C	missense	-0.15	0.15	68.0	0.023	BRCA2 repeat	rs144848		0.24 (ref)	0.2859	0.1289	0.2332	YES	BRCA2-MAGE-D1 complex,DNA binding,DNA recombination,DNA repair,H3 histone acetyltransferase activity,H4 histone acetyltransferase activity,cell cycle,cell cycle cytokinesis,centrosome,centrosome duplication,cytoplasm,double-strand break repair,double-strand break repair via homologous recombination,gamma-tubulin binding,histone H3 acetylation,histone H4 acetylation,histone acetyltransferase activity,homologous chromosome orientation involved in meiotic metaphase I plate congression,mammary gland development,multicellular organism growth,negative regulation of mammary gland epithelial cell proliferation,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,positive regulation of transcription, DNA-dependent,protease binding,protein binding,protein complex,regulation of S phase of mitotic cell cycle,response to estradiol stimulus,response to nutrient,secretory granule,single-stranded DNA binding,spermatogenesis		non-pathogenic,other	0.00001	5544.67	A=692, C=614		A=316/376, C=261/353	3	
chr13:32911476	G/A	G	SNV		BRCA2	exonic	1								8.33	p.Gly995Glu		48	G=0.9167, A=0.0833		Present				+	11	NM_000059.3	c.2984G>A	missense	-0.13	0.8	98.0	0.913	BRCA2 repeat								BRCA2-MAGE-D1 complex,DNA binding,DNA recombination,DNA repair,H3 histone acetyltransferase activity,H4 histone acetyltransferase activity,cell cycle,cell cycle cytokinesis,centrosome,centrosome duplication,cytoplasm,double-strand break repair,double-strand break repair via homologous recombination,gamma-tubulin binding,histone H3 acetylation,histone H4 acetylation,histone acetyltransferase activity,homologous chromosome orientation involved in meiotic metaphase I plate congression,mammary gland development,multicellular organism growth,negative regulation of mammary gland epithelial cell proliferation,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,positive regulation of transcription, DNA-dependent,protease binding,protein binding,protein complex,regulation of S phase of mitotic cell cycle,response to estradiol stimulus,response to nutrient,secretory granule,single-stranded DNA binding,spermatogenesis			0.02064	16.8537	G=44, A=4		G=20/24, A=1/3	2	
chr13:32913055	G/G	A	SNV		BRCA2	exonic	1								100.00	p.(=)		784	A=0.0, G=1.0		Present				+	11	NM_000059.3	c.4563A>G	synonymous	0.6				BRCA2 repeat	rs206075		0.026 (ref)	6.0E-4	0.0704	0.0242	YES	BRCA2-MAGE-D1 complex,DNA binding,DNA recombination,DNA repair,H3 histone acetyltransferase activity,H4 histone acetyltransferase activity,cell cycle,cell cycle cytokinesis,centrosome,centrosome duplication,cytoplasm,double-strand break repair,double-strand break repair via homologous recombination,gamma-tubulin binding,histone H3 acetylation,histone H4 acetylation,histone acetyltransferase activity,homologous chromosome orientation involved in meiotic metaphase I plate congression,mammary gland development,multicellular organism growth,negative regulation of mammary gland epithelial cell proliferation,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,positive regulation of transcription, DNA-dependent,protease binding,protein binding,protein complex,regulation of S phase of mitotic cell cycle,response to estradiol stimulus,response to nutrient,secretory granule,single-stranded DNA binding,spermatogenesis			0.00001	11830.4	A=0, G=784		A=0/0, G=440/344	1	
chr13:32915005	C/C	G	SNV		BRCA2	exonic	1								100.00	p.(=)		861	G=0.0, C=1.0		Present				+	11	NM_000059.3	c.6513G>C	synonymous	-1.1				BRCA2 repeat	rs206076		0.026 (ref)	6.0E-4	0.0713	0.0245	YES	BRCA2-MAGE-D1 complex,DNA binding,DNA recombination,DNA repair,H3 histone acetyltransferase activity,H4 histone acetyltransferase activity,cell cycle,cell cycle cytokinesis,centrosome,centrosome duplication,cytoplasm,double-strand break repair,double-strand break repair via homologous recombination,gamma-tubulin binding,histone H3 acetylation,histone H4 acetylation,histone acetyltransferase activity,homologous chromosome orientation involved in meiotic metaphase I plate congression,mammary gland development,multicellular organism growth,negative regulation of mammary gland epithelial cell proliferation,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,positive regulation of transcription, DNA-dependent,protease binding,protein binding,protein complex,regulation of S phase of mitotic cell cycle,response to estradiol stimulus,response to nutrient,secretory granule,single-stranded DNA binding,spermatogenesis			0.00001	13068.5	G=0, C=861		G=0/0, C=517/344	1	
chr13:32921024	T/C	T	SNV		BRCA2	exonic	1								29.49	p.Val2333Ala		1519	T=0.7051, C=0.2949		Present				+	13	NM_000059.3	c.6998T>C	missense	-0.1	0.63	64.0	0.001	BRCA2 repeat								BRCA2-MAGE-D1 complex,DNA binding,DNA recombination,DNA repair,H3 histone acetyltransferase activity,H4 histone acetyltransferase activity,cell cycle,cell cycle cytokinesis,centrosome,centrosome duplication,cytoplasm,double-strand break repair,double-strand break repair via homologous recombination,gamma-tubulin binding,histone H3 acetylation,histone H4 acetylation,histone acetyltransferase activity,homologous chromosome orientation involved in meiotic metaphase I plate congression,mammary gland development,multicellular organism growth,negative regulation of mammary gland epithelial cell proliferation,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,positive regulation of transcription, DNA-dependent,protease binding,protein binding,protein complex,regulation of S phase of mitotic cell cycle,response to estradiol stimulus,response to nutrient,secretory granule,single-stranded DNA binding,spermatogenesis			0.00001	2999.45	T=1071, C=448		T=544/527, C=233/215	1	
chr13:32929387	C/C	T	SNV		BRCA2	exonic	1								98.84	p.Val2466Ala		605	T=0.0116, C=0.9884		Present				+	14	NM_000059.3	c.7397T>C	missense	1.27	0.58	64.0	0.0	BRCA2 repeat	rs169547		0.022 (ref)	6.0E-4	0.0647	0.0223	YES	BRCA2-MAGE-D1 complex,DNA binding,DNA recombination,DNA repair,H3 histone acetyltransferase activity,H4 histone acetyltransferase activity,cell cycle,cell cycle cytokinesis,centrosome,centrosome duplication,cytoplasm,double-strand break repair,double-strand break repair via homologous recombination,gamma-tubulin binding,histone H3 acetylation,histone H4 acetylation,histone acetyltransferase activity,homologous chromosome orientation involved in meiotic metaphase I plate congression,mammary gland development,multicellular organism growth,negative regulation of mammary gland epithelial cell proliferation,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,positive regulation of transcription, DNA-dependent,protease binding,protein binding,protein complex,regulation of S phase of mitotic cell cycle,response to estradiol stimulus,response to nutrient,secretory granule,single-stranded DNA binding,spermatogenesis		untested	0.00001	8872.9	T=7, C=598		T=1/6, C=300/298	1	
chr15:88576185	C/C	G	SNV		NTRK3	exonic	1								100.00	p.(=)		430	G=0.0, C=1.0		Present				-	14	NM_001012338.2	c.1488C>G	synonymous	-2.01				Immunoglobulin I-set domain,Immunoglobulin domain,Leucine rich repeat N-terminal domain,Protein kinase domain,Protein tyrosine kinase	rs2229910		0.322 (ref)	0.3551	0.4048	0.3719	YES	ATP binding,Golgi membrane,cell differentiation,cellular response to retinoic acid,cochlea development,cytoplasm,integral to plasma membrane,mechanoreceptor differentiation,membrane fraction,modulation by virus of host transcription,multicellular organismal development,negative regulation of astrocyte differentiation,negative regulation of cell death,nervous system development,neuron fate specification,neuron migration,neurotrophin binding,nucleotide binding,plasma membrane,positive regulation of axon extension involved in regeneration,protein autophosphorylation,receptor activity,response to axon injury,response to corticosterone stimulus,response to ethanol,response to stress,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	6344.4	G=0, C=430		G=0/0, C=186/244	2	
chr15:89838236	G/A	G	SNV		FANCI	exonic	1								49.85	p.(=)		1988	G=0.5015, A=0.4985		Present				+	24	NM_001113378.1	c.2547G>A	synonymous	0.3					rs7183618		0.027 (ref)	0.0535	0.0087	0.0399	YES	DNA repair,cell cycle,nucleoplasm,nucleus,plasma membrane,protein binding			0.00001	9214.79	G=997, A=991		G=518/479, A=501/490	2	
chr16:3639139	G/G	A	SNV		SLX4	exonic	1								100.00	p.(=)		892	A=0.0, G=1.0		Present				-	12	NM_032444.2	c.4500T>C	synonymous	0.83				BTB/POZ domain	rs3810812		0.306 (ref)	0.4923	0.1406	0.3734	YES	3'-flap endonuclease activity,5'-flap endonuclease activity,DNA double-strand break processing involved in repair via single-strand annealing,DNA recombination,DNA repair,ERCC4-ERCC1 complex,Holliday junction resolvase complex,Slx1-Slx4 complex,crossover junction endodeoxyribonuclease activity,double-strand break repair via homologous recombination,enzyme activator activity,nuclear chromatin,nuclear chromosome, telomeric region,nucleotide-excision repair,nucleus,positive regulation of catalytic activity,protein binding			0.00001	13519.0	A=0, G=892		A=0/0, G=414/478	1	
chr16:3656482	T/T	C	SNV		SLX4	exonic	1								100.00	p.(=)		549	C=0.0, T=1.0		Present				-	3	NM_032444.2	c.753G>A	synonymous	-3.47				BTB/POZ domain	rs8061528		0.25 (ref)	0.203	0.2501	0.2189	YES	3'-flap endonuclease activity,5'-flap endonuclease activity,DNA double-strand break processing involved in repair via single-strand annealing,DNA recombination,DNA repair,ERCC4-ERCC1 complex,Holliday junction resolvase complex,Slx1-Slx4 complex,crossover junction endodeoxyribonuclease activity,double-strand break repair via homologous recombination,enzyme activator activity,nuclear chromatin,nuclear chromosome, telomeric region,nucleotide-excision repair,nucleus,positive regulation of catalytic activity,protein binding			0.00001	8266.87	C=0, T=549		C=0/0, T=280/269	4	
chr16:3788662	A/G	A	SNV		CREBBP	exonic	1								32.26	p.Ile1431Thr		403	A=0.6774, G=0.3226		Present				-	26	NM_004380.2	c.4292T>C	missense	2.13	0.0	89.0	0.997	Bromodomain,Domain of Unknown Function (DUF902),KIX domain,TAZ zinc finger,Zinc finger								MyoD binding,N-terminal peptidyl-lysine acetylation,RNA polymerase II activating transcription factor binding,RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription,RNA polymerase II transcription coactivator activity,RNA polymerase II transcription factor binding,RNA polymerase II transcription factor binding transcription factor activity involved in negative regulation of transcription,SMAD binding,acetyltransferase activity,cell proliferation,cellular lipid metabolic process,core promoter proximal region sequence-specific DNA binding,cytoplasm,embryonic digit morphogenesis,gene expression,histone acetylation,histone acetyltransferase activity,histone acetyltransferase complex,homeostatic process,innate immune response,interspecies interaction between organisms,metal ion binding,negative regulation of transcription from RNA polymerase II promoter,nuclear body,nuclear chromatin,nucleoplasm,nucleus,p53 binding,peroxisome proliferator activated receptor binding,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,protein binding,protein complex assembly,regulation of S phase,regulation of smoothened signaling pathway,regulation of transcription, DNA-dependent,response to hypoxia,sequence-specific DNA binding transcription factor activity,signal transducer activity,signal transduction,transcription coactivator activity,transcription factor binding,transferase activity,zinc ion binding	9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE		0.00001	920.552	A=273, G=130		A=133/140, G=50/80	3	
chr16:23619235	A/C	A	SNV		PALB2	exonic	1								47.81	p.(=)		274	A=0.5219, C=0.4781		Present				-	12	NM_024675.3	c.3300T>G	synonymous	-0.05					rs45516100		0.018 (ref)	0.0315	0.0212	0.028	YES	DNA binding,DNA recombination,DNA repair,double-strand break repair via homologous recombination,nucleoplasm,nucleus,protein binding		non-pathogenic	0.00001	1202.93	A=143, C=131		A=54/89, C=59/72	1	
chr16:23634293	C/T	C	SNV		PALB2	exonic	1								48.41	p.Gly998Glu		754	C=0.5159, T=0.4841		Present				-	9	NM_024675.3	c.2993G>A	missense	2.77	0.0	98.0	1.0		rs45551636		0.011 (ref)	0.024	0.0059	0.0179	YES	DNA binding,DNA recombination,DNA repair,double-strand break repair via homologous recombination,nucleoplasm,nucleus,protein binding		probable-non-pathogenic	0.00001	3366.57	C=389, T=365		C=188/201, T=173/192	2	
chr16:23641173	AGACT/A	AGACT	INDEL		PALB2	exonic	4	Deleterious	Loss-of-function						27.61	p.Cys768fs		1967	AGACT=0.7239, A=0.2761		Present				-	5	NM_024675.3	c.2298_2301delAGTC	frameshiftDeletion	0.33,0.25,-0.26,-0.07,2.14												DNA binding,DNA recombination,DNA repair,double-strand break repair via homologous recombination,nucleoplasm,nucleus,protein binding			0.00001	3458.25	AGACT=1424, A=543		AGACT=553/871, A=232/311	1	
chr16:23641461	C/G	C	SNV		PALB2	exonic	1								48.90	p.Glu672Gln		182	C=0.511, G=0.489		Present				-	5	NM_024675.3	c.2014G>C	missense	0.41	0.04	29.0	0.225		rs45532440		0.014 (ref)	0.0315	0.0071	0.0232	YES	DNA binding,DNA recombination,DNA repair,double-strand break repair via homologous recombination,nucleoplasm,nucleus,protein binding		probable-non-pathogenic	0.00001	814.351	C=93, G=89		C=48/45, G=52/37	1	
chr16:23646191	T/C	T	SNV		PALB2	exonic	1								55.31	p.Gln559Arg		179	T=0.4469, C=0.5531		Present				-	4	NM_024675.3	c.1676A>G	missense	-0.61	1.0	43.0	0.0		rs152451		0.147	0.0909	0.2208	0.1348	YES	DNA binding,DNA recombination,DNA repair,double-strand break repair via homologous recombination,nucleoplasm,nucleus,protein binding		probable-non-pathogenic	0.00001	970.301	T=80, C=99		T=50/30, C=55/44	2	
chr16:89849480	C/T	C	SNV		FANCA	exonic	1								51.29	p.Gly501Ser		427	C=0.4871, T=0.5129		Present				-	16	NM_000135.2	c.1501G>A	missense	-1.69	1.0	56.0	0.0	Fanconi anaemia group A protein	rs2239359		0.393 (ref)	0.381	0.3196	0.4823	YES	DNA repair,Fanconi anaemia nuclear complex,cytoplasm,female gonad development,male gonad development,male meiosis,nucleoplasm,nucleus,protein binding,protein complex assembly,regulation of cell proliferation			0.00001	2083.77	C=208, T=219		C=89/119, T=84/135	2	
chr16:89883007	A/T	A	SNV		FANCA	exonic	1								52.95	p.Val6Asp		1256	A=0.4705, T=0.5295		Present				-	1	NM_000135.2	c.17T>A	missense	-0.15	0.04	152.0	0.072	Fanconi anaemia group A protein	rs1800282		0.051 (ref)	0.0664	0.0143	0.05	YES	DNA repair,Fanconi anaemia nuclear complex,cytoplasm,female gonad development,male gonad development,male meiosis,nucleoplasm,nucleus,protein binding,protein complex assembly,regulation of cell proliferation			0.00001	6439.11	A=591, T=665		A=130/461, T=145/520	1	
chr17:7579472	G/C	G	SNV		TP53	exonic	1								50.38	p.Pro72Arg		1995	G=0.4962, C=0.5038		Present				-	4	NM_000546.5	c.215C>G	missense	1.36	0.6	103.0	0.083	P53 DNA-binding domain,P53 tetramerisation motif,P53 transactivation motif	rs1042522		0.398 (ref)	0.2548	0.4051	0.37	YES	ATP binding,B cell lineage commitment,DNA binding,DNA damage response, signal transduction by p53 class mediator,DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest,DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA strand annealing activity,DNA strand renaturation,ER overload response,MDM2 binding,PML body,RNA polymerase II transcription factor binding,Ras protein signal transduction,T cell differentiation in thymus,T cell lineage commitment,T cell proliferation involved in immune response,activation of caspase activity by cytochrome c,apoptotic process,base-excision repair,blood coagulation,cell aging,cell cycle arrest,cell cycle checkpoint,cell differentiation,cell proliferation,cellular protein localization,cellular response to UV,cellular response to drug,cellular response to glucose starvation,cellular response to hypoxia,cellular response to ionizing radiation,central nervous system development,chaperone binding,chromatin,chromatin assembly complex,chromatin binding,chromosome organization,copper ion binding,cytoplasm,cytosol,damaged DNA binding,determination of adult lifespan,double-strand break repair,embryo development ending in birth or egg hatching,endoplasmic reticulum,enzyme binding,gastrulation,histone acetyltransferase binding,histone deacetylase regulator activity,identical protein binding,in utero embryonic development,induction of apoptosis by intracellular signals,insoluble fraction,interspecies interaction between organisms,metal ion binding,mitochondrion,mitotic cell cycle G1/S transition DNA damage checkpoint,multicellular organism growth,multicellular organismal development,negative regulation of DNA replication,negative regulation of apoptotic process,negative regulation of cell growth,negative regulation of cell proliferation,negative regulation of fibroblast proliferation,negative regulation of helicase activity,negative regulation of neuroblast proliferation,negative regulation of transcription from RNA polymerase II promoter,negative regulation of transcription, DNA-dependent,negative regulation of transforming growth factor beta receptor signaling pathway,nuclear body,nuclear chromatin,nuclear matrix,nucleolus,nucleoplasm,nucleotide-excision repair,nucleus,oxidative stress-induced premature senescence,p53 binding,positive regulation of apoptotic process,positive regulation of cell aging,positive regulation of cell cycle arrest,positive regulation of histone deacetylation,positive regulation of neuron apoptosis,positive regulation of peptidyl-tyrosine phosphorylation,positive regulation of reactive oxygen species metabolic process,positive regulation of thymocyte apoptosis,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,protease binding,protein N-terminus binding,protein binding,protein complex,protein complex assembly,protein heterodimerization activity,protein import into nucleus, translocation,protein kinase binding,protein localization,protein phosphatase 2A binding,protein tetramerization,rRNA transcription,regulation of apoptotic process,regulation of cell cycle,regulation of mitochondrial membrane permeability,regulation of transcription, DNA-dependent,release of cytochrome c from mitochondria,replication fork,replicative senescence,response to DNA damage stimulus,response to X-ray,response to antibiotic,response to gamma radiation,sequence-specific DNA binding transcription factor activity,signal transduction by p53 class mediator resulting in induction of apoptosis,somitogenesis,transcription factor TFIID complex,transcription factor binding,transcription regulatory region DNA binding,ubiquitin protein ligase binding,zinc ion binding	1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine	non-pathogenic	0.00001	9490.42	G=990, C=1005		G=376/614, C=369/636	6	
chr17:29553485	A/A	G	SNV		NF1	exonic	1								100.00	p.(=)		947	G=0.0, A=1.0		Present				+	18	NM_001042492.2	c.2034G>A	synonymous	-2.42				GTPase-activator protein for Ras-like GTPase	rs2285892		0.471 (ref)	0.2891	0.3352	0.4163	YES	MAPKKK cascade,Ras GTPase activator activity,Ras protein signal transduction,Schwann cell development,actin cytoskeleton organization,adrenal gland development,artery morphogenesis,axon,brain development,camera-type eye morphogenesis,cell communication,cerebral cortex development,cognition,collagen fibril organization,cytoplasm,dendrite,extracellular matrix organization,forebrain astrocyte development,forebrain morphogenesis,heart development,intracellular,intrinsic to internal side of plasma membrane,liver development,metanephros development,myelination in peripheral nervous system,negative regulation of MAP kinase activity,negative regulation of MAPKKK cascade,negative regulation of Rac protein signal transduction,negative regulation of Ras protein signal transduction,negative regulation of angiogenesis,negative regulation of astrocyte differentiation,negative regulation of cell migration,negative regulation of endothelial cell proliferation,negative regulation of fibroblast proliferation,negative regulation of neuroblast proliferation,negative regulation of neurotransmitter secretion,negative regulation of oligodendrocyte differentiation,negative regulation of protein kinase activity,negative regulation of transcription factor import into nucleus,neural tube development,nucleus,osteoblast differentiation,peripheral nervous system development,phosphatidylinositol 3-kinase cascade,pigmentation,positive regulation of Ras GTPase activity,positive regulation of adenylate cyclase activity,positive regulation of apoptotic process,positive regulation of endothelial cell proliferation,positive regulation of neuron apoptosis,protein binding,regulation of Ras GTPase activity,regulation of angiogenesis,regulation of blood vessel endothelial cell migration,regulation of bone resorption,regulation of cell-matrix adhesion,regulation of glial cell differentiation,regulation of long-term neuronal synaptic plasticity,regulation of small GTPase mediated signal transduction,regulation of synaptic transmission, GABAergic,response to hypoxia,signal transduction,skeletal muscle tissue development,smooth muscle tissue development,spinal cord development,sympathetic nervous system development,visual learning,wound healing			0.00001	14329.1	G=0, A=947		G=0/0, A=445/502	1	
chr17:29553610	G/A	G	SNV		NF1	exonic	1								8.85	p.Arg720Gln		113	G=0.9115, A=0.0885		Present				+	18	NM_001042492.2	c.2159G>A	missense	2.61	0.35	43.0	0.938	GTPase-activator protein for Ras-like GTPase								MAPKKK cascade,Ras GTPase activator activity,Ras protein signal transduction,Schwann cell development,actin cytoskeleton organization,adrenal gland development,artery morphogenesis,axon,brain development,camera-type eye morphogenesis,cell communication,cerebral cortex development,cognition,collagen fibril organization,cytoplasm,dendrite,extracellular matrix organization,forebrain astrocyte development,forebrain morphogenesis,heart development,intracellular,intrinsic to internal side of plasma membrane,liver development,metanephros development,myelination in peripheral nervous system,negative regulation of MAP kinase activity,negative regulation of MAPKKK cascade,negative regulation of Rac protein signal transduction,negative regulation of Ras protein signal transduction,negative regulation of angiogenesis,negative regulation of astrocyte differentiation,negative regulation of cell migration,negative regulation of endothelial cell proliferation,negative regulation of fibroblast proliferation,negative regulation of neuroblast proliferation,negative regulation of neurotransmitter secretion,negative regulation of oligodendrocyte differentiation,negative regulation of protein kinase activity,negative regulation of transcription factor import into nucleus,neural tube development,nucleus,osteoblast differentiation,peripheral nervous system development,phosphatidylinositol 3-kinase cascade,pigmentation,positive regulation of Ras GTPase activity,positive regulation of adenylate cyclase activity,positive regulation of apoptotic process,positive regulation of endothelial cell proliferation,positive regulation of neuron apoptosis,protein binding,regulation of Ras GTPase activity,regulation of angiogenesis,regulation of blood vessel endothelial cell migration,regulation of bone resorption,regulation of cell-matrix adhesion,regulation of glial cell differentiation,regulation of long-term neuronal synaptic plasticity,regulation of small GTPase mediated signal transduction,regulation of synaptic transmission, GABAergic,response to hypoxia,signal transduction,skeletal muscle tissue development,smooth muscle tissue development,spinal cord development,sympathetic nervous system development,visual learning,wound healing			0.00091	30.3993	G=103, A=10		G=49/54, A=5/5	2	
chr17:37618478	G/A	G	SNV		CDK12	exonic	1								9.09	p.Asp52Asn		33	G=0.9091, A=0.0909		Present				+	1	NM_016507.3	c.154G>A	missense	1.19	0.0	23.0	0.997	Protein kinase domain,Protein tyrosine kinase								ATP binding,RNA polymerase II carboxy-terminal domain kinase activity,RNA splicing,cyclin binding,cyclin-dependent protein kinase activity,mRNA processing,nuclear cyclin-dependent protein kinase holoenzyme complex,nuclear speck,nucleolus,nucleotide binding,nucleus,phosphorylation of RNA polymerase II C-terminal domain,protein autophosphorylation,protein binding,protein kinase activity,regulation of MAP kinase activity			0.03647	14.3806	G=30, A=3		G=15/15, A=1/2	1	
chr17:37627387	A/G	A	SNV		CDK12	exonic	1								51.28	p.(=)		1999	A=0.4872, G=0.5128		Present				+	2	NM_016507.3	c.1302A>G	synonymous	0.54				Protein kinase domain,Protein tyrosine kinase	rs56158954		0.009 (ref)	0.0198	0.0048	0.0147	YES	ATP binding,RNA polymerase II carboxy-terminal domain kinase activity,RNA splicing,cyclin binding,cyclin-dependent protein kinase activity,mRNA processing,nuclear cyclin-dependent protein kinase holoenzyme complex,nuclear speck,nucleolus,nucleotide binding,nucleus,phosphorylation of RNA polymerase II C-terminal domain,protein autophosphorylation,protein binding,protein kinase activity,regulation of MAP kinase activity			0.00001	9783.74	A=974, G=1025		A=469/505, G=493/532	1	
chr17:37880216	G/A	G	SNV		ERBB2	exonic	1								34.93	p.Val754Met		209	G=0.6507, A=0.3493		Present				+	19	NM_004448.3	c.2260G>A	missense	2.48	0.01	21.0	1.0	Furin-like cysteine rich region,Protein kinase domain,Protein tyrosine kinase,Receptor L domain								ATP binding,ErbB-3 class receptor binding,Hsp90 protein binding,RNA polymerase I core binding,apical plasma membrane,axon guidance,basal plasma membrane,basolateral plasma membrane,cell proliferation,cell surface receptor linked signaling pathway,cytoplasm,endosome membrane,enzyme linked receptor protein signaling pathway,epidermal growth factor receptor signaling pathway,epidermal growth factor-activated receptor activity,estrus,glial cell differentiation,glycoprotein binding,growth factor binding,heart development,identical protein binding,integral to membrane,lateral loop,liver development,mammary gland development,mammary gland involution,membrane raft,microvillus,motor axon guidance,myelination,negative regulation of apoptotic process,negative regulation of immature T cell proliferation in thymus,nervous system development,neuromuscular junction development,nucleotide binding,nucleus,perinuclear region of cytoplasm,peripheral nervous system development,phosphatidylinositol 3-kinase cascade,phosphatidylinositol-mediated signaling,plasma membrane,positive regulation of MAP kinase activity,positive regulation of MAPKKK cascade,positive regulation of Ras protein signal transduction,positive regulation of cell adhesion,positive regulation of cell growth,positive regulation of epithelial cell proliferation,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of transcription from RNA polymerase I promoter,positive regulation of transcription from RNA polymerase III promoter,positive regulation of translation,postsynaptic membrane,protein C-terminus binding,protein autophosphorylation,protein binding,protein dimerization activity,protein heterodimerization activity,protein phosphatase binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,receptor complex,receptor signaling protein tyrosine kinase activity,regulation of ERK1 and ERK2 cascade,regulation of angiogenesis,regulation of microtubule-based process,regulation of transcription, DNA-dependent,response to axon injury,response to drug,response to progesterone stimulus,signal transduction,skeletal muscle tissue development,sympathetic nervous system development,tongue development,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway,transmembrane signaling receptor activity,ubiquitin protein ligase binding,wound healing	Lapatinib,Trastuzumab		0.00001	537.5	G=136, A=73		G=59/77, A=33/40	1	
chr17:37881077	C/A	C	SNV		ERBB2	exonic	1								4.55	p.(=)		1605	C=0.9545, A=0.0455		Present				+	20	NM_004448.3	c.2406C>A	synonymous	1.23				Furin-like cysteine rich region,Protein kinase domain,Protein tyrosine kinase,Receptor L domain								ATP binding,ErbB-3 class receptor binding,Hsp90 protein binding,RNA polymerase I core binding,apical plasma membrane,axon guidance,basal plasma membrane,basolateral plasma membrane,cell proliferation,cell surface receptor linked signaling pathway,cytoplasm,endosome membrane,enzyme linked receptor protein signaling pathway,epidermal growth factor receptor signaling pathway,epidermal growth factor-activated receptor activity,estrus,glial cell differentiation,glycoprotein binding,growth factor binding,heart development,identical protein binding,integral to membrane,lateral loop,liver development,mammary gland development,mammary gland involution,membrane raft,microvillus,motor axon guidance,myelination,negative regulation of apoptotic process,negative regulation of immature T cell proliferation in thymus,nervous system development,neuromuscular junction development,nucleotide binding,nucleus,perinuclear region of cytoplasm,peripheral nervous system development,phosphatidylinositol 3-kinase cascade,phosphatidylinositol-mediated signaling,plasma membrane,positive regulation of MAP kinase activity,positive regulation of MAPKKK cascade,positive regulation of Ras protein signal transduction,positive regulation of cell adhesion,positive regulation of cell growth,positive regulation of epithelial cell proliferation,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of transcription from RNA polymerase I promoter,positive regulation of transcription from RNA polymerase III promoter,positive regulation of translation,postsynaptic membrane,protein C-terminus binding,protein autophosphorylation,protein binding,protein dimerization activity,protein heterodimerization activity,protein phosphatase binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,receptor complex,receptor signaling protein tyrosine kinase activity,regulation of ERK1 and ERK2 cascade,regulation of angiogenesis,regulation of microtubule-based process,regulation of transcription, DNA-dependent,response to axon injury,response to drug,response to progesterone stimulus,signal transduction,skeletal muscle tissue development,sympathetic nervous system development,tongue development,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway,transmembrane signaling receptor activity,ubiquitin protein ligase binding,wound healing	Lapatinib,Trastuzumab		0.00021	36.8175	C=1532, A=73		C=817/715, A=42/31	3	
chr17:41223094	T/C	T	SNV		BRCA1	exonic	1								48.18	p.Ser1634Gly		1322	T=0.5182, C=0.4818		Present				-	16	NM_007300.3	c.4900A>G	missense	0.13	0.03	56.0	0.58	BRCA1 C Terminus (BRCT) domain,Zinc finger	rs1799966		0.327	0.3266	0.2426	0.2982	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		non-pathogenic	0.00001	5809.98	T=685, C=637		T=352/333, C=348/289	1	
chr17:41234470	A/G	A	SNV		BRCA1	exonic	1								47.50	p.(=)		979	A=0.525, G=0.475		Present				-	12	NM_007300.3	c.4308T>C	synonymous	0.13				BRCA1 C Terminus (BRCT) domain,Zinc finger	rs1060915		0.304 (ref)	0.326	0.1888	0.2796	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		untested	0.00001	4216.27	A=514, G=465		A=249/265, G=232/233	2	
chr17:41244000	T/C	T	SNV		BRCA1	exonic	1								51.75	p.Lys1183Arg		1909	T=0.4825, C=0.5175		Present				-	10	NM_007300.3	c.3548A>G	missense	-0.44	1.0	26.0	0.0	BRCA1 C Terminus (BRCT) domain,Zinc finger	rs16942,rs80357956		0.324 (ref)	0.3244	0.2383	0.2952	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		non-pathogenic	0.00001	9469.5	T=921, C=988		T=451/470, C=489/499	3	
chr17:41244435	T/C	T	SNV		BRCA1	exonic	1								51.31	p.Glu1038Gly		1224	T=0.4869, C=0.5131		Present				-	10	NM_007300.3	c.3113A>G	missense	0.11	0.02	98.0	0.158	BRCA1 C Terminus (BRCT) domain,Zinc finger	rs16941,rs80357920		0.303 (ref)	0.3255	0.1884	0.279	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		non-pathogenic	0.00001	5978.92	T=596, C=628		T=300/296, C=319/309	2	
chr17:41244936	G/A	G	SNV		BRCA1	exonic	1								48.90	p.Pro871Leu		816	G=0.511, A=0.489		Present				-	10	NM_007300.3	c.2612C>T	missense	0.94	1.0	98.0	0.0	BRCA1 C Terminus (BRCT) domain,Zinc finger	rs799917,rs80357962		0.483	0.3359	0.2	0.4932	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		non-pathogenic	0.00001	3679.37	G=417, A=399		G=209/208, A=176/223	2	
chr17:41245237	A/G	A	SNV		BRCA1	exonic	1								50.84	p.(=)		712	A=0.4916, G=0.5084		Present				-	10	NM_007300.3	c.2311T>C	synonymous	-0.83				BRCA1 C Terminus (BRCT) domain,Zinc finger	rs16940		0.302 (ref)	0.3237	0.1877	0.2776	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		untested	0.00001	3434.24	A=350, G=362		A=182/168, G=179/183	2	
chr17:41245466	G/A	G	SNV		BRCA1	exonic	1								44.57	p.(=)		1999	G=0.5543, A=0.4457		Present				-	10	NM_007300.3	c.2082C>T	synonymous	-0.08				BRCA1 C Terminus (BRCT) domain,Zinc finger	rs1799949		0.324 (ref)	0.3244	0.2396	0.2957	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		untested	0.00001	7795.23	G=1108, A=891		G=603/505, A=497/394	1	
chr17:41245471	C/T	C	SNV		BRCA1	exonic	1								45.17	p.Asp693Asn		1997	C=0.5483, T=0.4517		Present				-	10	NM_007300.3	c.2077G>A	missense	0.13	0.05	23.0	0.001	BRCA1 C Terminus (BRCT) domain,Zinc finger	rs4986850		0.039	0.0702	0.0232	0.0543	YES	BRCA1-A complex,BRCA1-BARD1 complex,DNA binding,DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator,DNA damage response, signal transduction resulting in induction of apoptosis,DNA recombination,DNA repair,DNA replication,G2/M transition DNA damage checkpoint,RNA binding,androgen receptor binding,androgen receptor signaling pathway,apoptotic process,brain development,cell cycle,cellular response to indole-3-methanol,centrosome cycle,chordate embryonic development,chromosome segregation,condensed nuclear chromosome,cytoplasm,damaged DNA binding,dosage compensation, by inactivation of X chromosome,double-strand break repair,double-strand break repair via homologous recombination,enzyme binding,filamentous actin,focal adhesion,gamma-tubulin ring complex,intracellular,ligase activity,metal ion binding,mitochondrial matrix,negative regulation of centriole replication,negative regulation of fatty acid biosynthetic process,negative regulation of histone H3-K9 methylation,negative regulation of transcription, DNA-dependent,nucleoplasm,nucleus,plasma membrane,positive regulation of DNA repair,positive regulation of cell cycle arrest,positive regulation of histone H3-K4 methylation,positive regulation of histone H3-K9 acetylation,positive regulation of histone H4-K16 acetylation,positive regulation of histone H4-K20 methylation,positive regulation of histone acetylation,positive regulation of protein ubiquitination,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,postreplication repair,protein K6-linked ubiquitination,protein autoubiquitination,protein binding,protein complex,protein ubiquitination,regulation of apoptotic process,regulation of cell motility,regulation of cell proliferation,regulation of transcription from RNA polymerase II promoter,regulation of transcription from RNA polymerase III promoter,response to DNA damage stimulus,response to estradiol stimulus,response to estrogen stimulus,response to ionizing radiation,response to lipid,response to nutrient,ribonucleoprotein complex,ruffle,substrate adhesion-dependent cell spreading,transcription coactivator activity,transcription regulatory region DNA binding,tubulin binding,ubiquitin ligase complex,ubiquitin protein ligase binding,ubiquitin-protein ligase activity,zinc ion binding		non-pathogenic	0.00001	7953.99	C=1095, T=902		C=590/505, T=500/402	1	
chr17:56435187	T/C	T	SNV		RNF43	exonic	1								29.13	p.(=)		1768	T=0.7087, C=0.2913		Present				-	9	NM_017763.4	c.1950A>G	synonymous	0.3				Zinc finger								endoplasmic reticulum,endoplasmic reticulum membrane,integral to membrane,ligase activity,membrane,metal ion binding,nuclear envelope,nucleus,protein binding,zinc ion binding			0.00001	3398.09	T=1253, C=515		T=634/619, C=275/240	1	
chr17:56438301	G/A	G	SNV		RNF43	exonic	1								45.90	p.Pro231Leu		1050	G=0.541, A=0.459		Present				-	7	NM_017763.4	c.692C>T	missense	0.94	0.07	98.0	0.76	Zinc finger	rs2680701		0.102 (ref)	0.2023	0.0481	0.1501	YES	endoplasmic reticulum,endoplasmic reticulum membrane,integral to membrane,ligase activity,membrane,metal ion binding,nuclear envelope,nucleus,protein binding,zinc ion binding			0.00001	4272.07	G=568, A=482		G=264/304, A=183/299	2	
chr18:48604751	A/G	A	SNV		SMAD4	exonic	1								31.08	p.Ile525Val		415	A=0.6892, G=0.3108		Present				+	12	NM_005359.5	c.1573A>G	missense	2.33	0.11	29.0	0.0	MH1 domain,MH2 domain	rs149755320			0.0012	2.0E-4	8.0E-4		BMP signaling pathway,DNA binding,I-SMAD binding,R-SMAD binding,SMAD protein complex,SMAD protein complex assembly,SMAD protein signal transduction,activin responsive factor complex,anterior/posterior pattern specification,centrosome,chromatin binding,collagen binding,core promoter proximal region sequence-specific DNA binding,cytoplasm,cytosol,developmental growth,endoderm development,formation of anatomical boundary,gastrulation with mouth forming second,identical protein binding,in utero embryonic development,intracellular,kidney development,mesoderm development,metanephric mesenchyme morphogenesis,negative regulation of cell death,negative regulation of cell growth,negative regulation of cell proliferation,negative regulation of protein catabolic process,negative regulation of transcription, DNA-dependent,nephrogenic mesenchyme morphogenesis,neuron fate commitment,nucleolus,nucleoplasm,nucleus,palate development,positive regulation of SMAD protein import into nucleus,positive regulation of epithelial to mesenchymal transition,positive regulation of pathway-restricted SMAD protein phosphorylation,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription, DNA-dependent,positive regulation of transforming growth factor beta receptor signaling pathway,protein binding,protein binding transcription factor activity,protein homodimerization activity,regulation of binding,regulation of transforming growth factor beta receptor signaling pathway,regulation of transforming growth factor beta2 production,response to hypoxia,response to transforming growth factor beta stimulus,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,somite rostral/caudal axis specification,tissue morphogenesis,transcription factor complex,transcription regulatory region DNA binding,transforming growth factor beta receptor signaling pathway,transforming growth factor beta receptor, common-partner cytoplasmic mediator activity			0.00001	889.871	A=286, G=129		A=159/127, G=75/54	1	
chr19:15271771	G/A	G	SNV		NOTCH3	exonic	1								50.90	p.Ala2223Val		1998	G=0.491, A=0.509		Present				-	33	NM_000435.2	c.6668C>T	missense	0.08	0.18	64.0	0.001	Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1044009		0.368 (ref)	0.1987	0.397	0.2651	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	9663.63	G=981, A=1017		G=420/561, A=478/539	1	
chr19:15278057	G/G	A	SNV		NOTCH3	splicesite_3	1								99.89			914	A=0.0011, G=0.9989		Present				-	29	NM_000435.2			0.62				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1548555		0.133 (ref)	0.1034	0.0236	0.0763	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	13846.1	A=1, G=913		A=0/1, G=433/480	2	
chr19:15278113	G/T	G	SNV		NOTCH3	exonic	1								9.83	p.Pro1770Gln		1994	G=0.9017, T=0.0983		Present				-	29	NM_000435.2	c.5309C>A	missense	2.19	0.0	76.0	1.0	Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein								Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	460.217	G=1798, T=196		G=798/1000, T=83/113	2	
chr19:15285052	C/C	T	SNV		NOTCH3	exonic	1								100.00	p.(=)		1998	T=0.0, C=1.0		Present				-	25	NM_000435.2	c.4563A>G	synonymous	-1.43				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1044006		0.133 (ref)	0.1002	0.0223	0.0739	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	30457.7	T=0, C=1998		T=0/0, C=883/1115	1	
chr19:15285059	A/G	A	SNV		NOTCH3	exonic	1								27.08	p.Leu1519Pro		1998	A=0.7292, G=0.2708		Present				-	25	NM_000435.2	c.4556T>C	missense	1.81	0.0	98.0	0.984	Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs367543285							Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration		untested	0.00001	3405.91	A=1457, G=541		A=701/756, G=267/274	1	
chr19:15292437	C/C	T	SNV		NOTCH3	exonic	1								100.00	p.(=)		992	T=0.0, C=1.0		Present				-	17	NM_000435.2	c.2742A>G	synonymous	-4.38				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1043997		0.233 (ref)	0.1299	0.3636	0.2095	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	15101.6	T=0, C=992		T=0/0, C=531/461	1	
chr19:15295134	G/A	G	SNV		NOTCH3	exonic	1								39.63	p.(=)		656	G=0.6037, A=0.3963		Present				-	16	NM_000435.2	c.2538C>T	synonymous	-0.59				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1043996		0.462 (ref)	0.2849	0.2762	0.4336	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	2102.21	G=396, A=260		G=223/173, A=155/105	1	
chr19:15302844	C/C	T	SNV		NOTCH3	exonic	1								100.00	p.(=)		1990	T=0.0, C=1.0		Present				-	4	NM_000435.2	c.606A>G	synonymous	-2.59				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs1043994		0.144 (ref)	0.1224	0.0878	0.1107	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	30143.4	T=0, C=1990		T=0/0, C=859/1131	1	
chr19:15303225	G/A	G	SNV		NOTCH3	exonic	1								48.07	p.(=)		1999	G=0.5193, A=0.4807		Present				-	3	NM_000435.2	c.303C>T	synonymous	-0.55				Ankyrin repeat,Calcium-binding EGF domain,EGF-like domain,LNR domain,NOTCH protein	rs3815188		0.238 (ref)	0.147	0.2544	0.1834	YES	Golgi lumen,Notch receptor processing,Notch signaling pathway,calcium ion binding,cytosol,endoplasmic reticulum lumen,extracellular region,forebrain development,gene expression,integral to membrane,multicellular organismal development,negative regulation of neuron differentiation,neuron fate commitment,nucleoplasm,nucleus,plasma membrane,protein binding,receptor activity,regulation of developmental process,regulation of transcription, DNA-dependent,tissue regeneration			0.00001	8818.6	G=1038, A=961		G=511/527, A=506/455	2	
chr19:30314666	C/T	C	SNV		CCNE1	exonic	1								48.39	p.(=)		498	C=0.5161, T=0.4839		Present				+	12	NM_001238.2	c.1215C>T	synonymous	-1.18				Cyclin	rs7257694		0.216 (ref)	0.3899	0.111	0.2954	YES	DNA-dependent DNA replication initiation,G1/S transition of mitotic cell cycle,Wnt receptor signaling pathway,androgen receptor binding,androgen receptor signaling pathway,antral ovarian follicle growth,cell division,cellular response to nutrient,centrosome,cyclin-dependent protein kinase holoenzyme complex,cyclin-dependent protein kinase regulator activity,cytoplasm,cytosol,kinase activity,liver development,mitotic cell cycle,nucleolus,nucleoplasm,nucleus,organ regeneration,positive regulation of cell differentiation,positive regulation of transcription, DNA-dependent,protein binding,protein kinase binding,protein phosphorylation,regulation of cyclin-dependent protein kinase activity,regulation of transcription involved in G1/S phase of mitotic cell cycle,response to corticosterone stimulus,response to cytokine stimulus,response to drug,response to estradiol stimulus,response to ethanol,response to methylmercury,response to organic nitrogen,response to progesterone stimulus,response to purine-containing compound,response to vitamin E,transcription coactivator activity			0.00001	2206.15	C=257, T=241		C=146/111, T=138/103	1	
chr20:36030939	C/C	G	SNV		SRC	exonic	1								100.00	p.(=)		1989	G=0.0, C=1.0		Present				+	12	NM_198291.2	c.1218G>C	synonymous	-2.02				Protein kinase domain,Protein tyrosine kinase,SH2 domain,SH3 domain,Variant SH3 domain	rs1885257		0.012 (ref)					ATP binding,Ras protein signal transduction,SH2 domain binding,SH3/SH2 adaptor activity,T cell costimulation,axon guidance,blood coagulation,bone resorption,branching involved in mammary gland duct morphogenesis,caveola,cell adhesion,cell cycle,cell junction assembly,cellular membrane organization,cytoplasm,cytoskeleton,cytosol,ephrin receptor binding,epidermal growth factor receptor signaling pathway,fibroblast growth factor receptor signaling pathway,forebrain development,heme binding,integrin binding,interspecies interaction between organisms,intracellular protein kinase cascade,ion channel binding,kinase activity,leukocyte migration,mitochondrial inner membrane,mitochondrion,nerve growth factor receptor signaling pathway,non-membrane spanning protein tyrosine kinase activity,nucleotide binding,nucleus,oogenesis,peptidyl-tyrosine phosphorylation,phosphorylation,plasma membrane,platelet activation,positive regulation of integrin activation,protein binding,protein kinase activity,protein phosphorylation,protein tyrosine kinase activity,receptor binding,regulation of bone resorption,regulation of intracellular estrogen receptor signaling pathway,regulation of vascular permeability,response to interleukin-1,signal complex assembly,signal transduction,uterus development	(2E)-N-{4-(3-bromophenyl)aminoquinazolin-6-yl}-4-(dimethylamino)but-2-enamide,1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo3,4-dpyrimidin-4-amine,1-1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl-3-naphthalen-1-ylurea,1-1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl-3-phenylurea,1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo3,4-DPyrimidin-4-Ylamine,1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo3,4-dpyrimidin-4-amine,1-cyclopentyl-3-(1H-pyrrolo2,3-bpyridin-5-yl)-1H-pyrazolo3,4-dpyrimidin-4-amine,2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE,3-4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO3,4-DPYRIMIDIN-3-YLPHENOL,4-(4-METHYL-1-PIPERAZINYL)METHYL-N-3-4-(3-PYRIDINYL)-2-PYRIMIDINYLAMINOPHENYL-BENZAMIDE,4-({4-(5-cyclopropyl-1H-pyrazol-3-yl)aminoquinazolin-2-yl}amino)phenylacetonitrile,Citric Acid,DPI59,Dasatinib,ISO24,Malonic acid,N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE,N-4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL-ACRYLAMIDE,N6-Benzyl Adenosine-5'-Diphosphate,Oxalic Acid,PAS219,PASBN,Phenylphosphate,Phosphonotyrosine,Purvalanol A,RU78191,RU78262,RU78299,RU78300,RU78783,RU79072,RU79073,RU79256,RU81843,RU82129,RU82197,RU82209,RU83876,RU84687,RU85053,RU85493,RU90395		0.00001	30112.6	G=0, C=1989		G=0/0, C=1000/989	2	
chrX:66942826		T	GENE_EXPRESSION		AR								AR.E7E8				773				NoCall			2.4104e-07																						0.0					
chrX:66943610	C/T	C	SNV		AR	exonic	1								4.55	p.Ala897Val		220	C=0.9545, T=0.0455		Present				+	8	NM_000044.3	c.2690C>T	missense	2.4	0.06	64.0	0.978	Androgen receptor,Ligand-binding domain of nuclear hormone receptor,Zinc finger								DNA binding,activation of prostate induction by androgen receptor signaling pathway,androgen binding,androgen receptor activity,androgen receptor binding,androgen receptor signaling pathway,axon,beta-catenin binding,cell death,cell growth,cell proliferation,cell-cell signaling,cytoplasm,dendrite,enzyme binding,epithelial cell differentiation involved in prostate gland development,gene expression,in utero embryonic development,lateral sprouting involved in mammary gland duct morphogenesis,male genitalia morphogenesis,male gonad development,male sex differentiation,male somatic sex determination,mammary gland alveolus development,metal ion binding,morphogenesis of an epithelial fold,negative regulation of apoptotic process,negative regulation of epithelial cell proliferation,negative regulation of integrin biosynthetic process,nuclear chromatin,nucleoplasm,nucleus,organ formation,positive regulation of MAPKKK cascade,positive regulation of NF-kappaB transcription factor activity,positive regulation of cell proliferation,positive regulation of insulin-like growth factor receptor signaling pathway,positive regulation of integrin biosynthetic process,positive regulation of intracellular estrogen receptor signaling pathway,positive regulation of phosphorylation,positive regulation of transcription from RNA polymerase II promoter,positive regulation of transcription from RNA polymerase III promoter,positive regulation of transcription, DNA-dependent,prostate gland development,prostate gland epithelium morphogenesis,prostate gland growth,protein binding,protein dimerization activity,receptor activity,receptor binding,regulation of catalytic activity,regulation of developmental growth,regulation of establishment of protein localization in plasma membrane,regulation of prostatic bud formation,response to insulin stimulus,sequence-specific DNA binding,sequence-specific DNA binding transcription factor activity,sex differentiation,signal transduction,tertiary branching involved in mammary gland duct morphogenesis,transcription factor binding,transcription regulatory region DNA binding,transcription, DNA-dependent,transport,zinc ion binding	(2S)-2-hydroxy-2-methyl-N-4-nitro-3-(trifluoromethyl)phenyl-3-(pentafluorophenoxy)propanamide,(2S)-3-(4-chloro-3-fluorophenoxy)-N-4-cyano-3-(trifluoromethyl)phenyl-2-hydroxy-2-methylpropanamide,(2S)-3-4-(acetylamino)phenoxy-2-hydroxy-2-methyl-N-4-nitro-3-(trifluoromethyl)phenylpropanamide,(2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide,(2r)-N-4-Cyano-3-(Trifluoromethyl)Phenyl-3-(4-Fluorophenyl)Sulfonyl-2-Hydroxy-2-Methylpropanamide,(3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE,(5S,8R,9S,10S,13R,14S,17S)-13-{2-(3,5-DIFLUOROBENZYL)OXYETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTAAPHENANTHREN-3-ONE,(R)-3-BROMO-2-HYDROXY-2-METHYL-N-4-NITRO-3-(TRIFLUOROMETHYL)PHENYLPROPANAMIDE,1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO3,4-DPYRIMIDIN-4-AMINE,17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE,2-CHLORO-4-(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO1,2-CIMIDAZOL-2(3H)-YL-3-METHYLBENZONITRILE,2-chloro-4-{(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo1,2-c1,3oxazol-3-ylideneamino}-3-methylbenzonitrile,3-(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO3,4-DPYRIMIDIN-3-YL)METHYLPHENOL,4-(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO1,2-CIMIDAZOL-2(3H)-YL-1-NAPHTHONITRILE,4-{(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propylamino}-2-(trifluoromethyl)benzonitrile,6-BIS(2,2,2-TRIFLUOROETHYL)AMINO-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE,Bicalutamide,Boldenone,Calusterone,Cyproterone,Danazol,Delta1-dihydrotestosterone,Dihydrotestosterone,Drospirenone,Drostanolone,Fludrocortisone,Flufenamic Acid,Fluoxymesterone,Flutamide,Levonorgestrel,Methyltestosterone,Methyltrienolone,Nandrolone decanoate,Nandrolone phenpropionate,Nilutamide,Oxandrolone,S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-4-NITRO-3-(TRIFLUOROMETHYL)PHENYLPROPANAMIDE,Spironolactone,Testosterone,Testosterone Propionate		0.07026	11.5328	C=210, T=10		C=104/106, T=3/7	1	
chrX:76909596	C/T	C	SNV		ATRX	exonic	1								5.22	p.Glu1437Lys		134	C=0.9478, T=0.0522		Present				-	14	NM_000489.4	c.4309G>A	missense	2.33	0.03	56.0	0.321	Helicase conserved C-terminal domain,SNF2 family N-terminal domain								ATP binding,DNA binding,DNA helicase activity,DNA methylation,DNA recombination,DNA repair,chromatin binding,chromo shadow domain binding,forebrain development,helicase activity,hydrolase activity,metal ion binding,nuclear chromosome,nuclear heterochromatin,nucleotide binding,nucleus,protein binding,regulation of transcription, DNA-dependent,zinc ion binding			0.0863	10.64	C=127, T=7		C=111/16, T=4/3	1	
